bnab_ID;binding_site;PDB;donor;clonal_lineage;isol_paper;neutr_feature;germ_paper;germ_software_db;V_best_heavy;D_best_heavy;J_best_heavy;CDR3_heavy_aa_len;CDR3_heavy_aa;V_best_light;J_best_light;CDR3_light_aa_len;CDR3_light_aa;light_chain_type;Aliases;LANL_comments;heavy_seq_aa;heavy_seq_nt;light_seq_aa;light_seq_nt;AuC
10-1074;gp120 V3 // V3 glycan (V3g);4FQ2(10-1074 Fab),5T3Z(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074),5T3X(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);17 ;PGT121;Mouquet2012a(23115339) ;10-1074 contacts,10-1074 neutralization,10-1074 signature predictions (West2013),hypervariable loop characteristic correlations with bNAb sensitivity,Key sites for PGT121-like and 10-1074-like mAbs,V3 Signature Analysis Summary;Mouquet2012a(23115339) ;IgBlast IMGT/V-QUEST;IGHV4-59*01;IGHD3-3,IGHD16;IGHJ6*03;24.0;ARRGQRIYGVVSFGEFFYYYSMDV;IGLV3-21*02;IGLJ3*02;12.0;HMWDSRSGFSWS;L;10.1074; ;QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGY;ACCGGTGTACATTCCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAACCTTCGGAGACCCTGTCCGTCACCTGCAGTGTCTCTGGAGATTCCATGAATAATTACTACTGGACTTGGATCCGGCAGTCCCCCGGAAAGGGACTGGAGTGGATAGGCTATATCTCTGACAGAGAATCAGCGACTTACAACCCCTCCCTCAATAGTCGAGTCGTCATATCACGAGACACGTCGAAAAACCAATTGTCCCTAAAATTAAACTCCGTCACCCCTGCGGACACGGCCGTCTATTACTGTGCGACAGCGCGCCGAGGACAGAGGATTTATGGAGTGGTTTCCTTTGGAGAGTTCTTCTACTACTACTCCATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCCTCAGCGTCGAC;SYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRP;ACCGGTTCTGTGACCTCCTATGTGCGCCCGCTGTCAGTGGCCCTGGGGGAGACGGCCAGGATTTCCTGTGGACGACAGGCCCTTGGAAGTAGAGCTGTTCAGTGGTATCAACATAGGCCAGGCCAGGCCCCTATATTGCTCATTTATAATAATCAAGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCACCCCTGATATTAATTTTGGGACCAGGGCCACCCTGACCATCAGCGGGGTCGAAGCCGGGGATGAAGCCGACTATTACTGTCACATGTGGGATAGTAGAAGTGGCTTCAGTTGGTCTTTCGGCGGGGCGACCAGGCTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCGAG;200.533906518964
10E8;gp41 MPER (membrane proximal external region);4U6G(10E8 Fab in complex with a hydrocarbon-stapled HIV-1 gp41 MPER peptide),5IQ7(10E8-S74W Fab in complex with an HIV-1 gp41 peptide),5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide),4G6F(Fab 10E8 complexed with gp41 peptide);N152 ;10E8;Huang2012a(23151583) ;10E8 contacts,10E8 residue prediction,10E8 signature predictions (West2013),hypervariable loop characteristic correlations with bNAb sensitivity,Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs,Signature Analysis Summary,Sites affecting neutralization of 10E8;Huang2012a(23151583) ;IMGT/V-QUEST;IGHV3-15*05;IGHD3-3*01;IGHJ1*01;22.0;TGKYYDFWSGYPPGEEYFQD;IGLV3-19*01;IGLJ3*02;12.0;SSRDKSGSRLSV;L;; ;EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGR;GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCTGGAGGATCCCTTAGACTCTCATGTTCAGCCTCTGGTTTCGACTTCGATAACGCCTGGATGACTTGGGTCCGCCAGCCTCCAGGGAAGGGCCTCGAATGGGTTGGTCGTATTACGGGTCCAGGTGAAGGTTGGTCAGTGGACTATGCTGCACCCGTGGAAGGCAGATTTACCATCTCGAGACTCAATTCAATAAATTTCTTATATTTGGAGATGAACAATTTAAGAATGGAAGACTCAGGCCTTTACTTCTGTGCCCGCACGGGAAAATATTATGATTTTTGGAGTGGCTATCCGCCGGGAGAAGAATACTTCCAAGACTGGGGCCGGGGCACCCTGGTCACCGTCTCCTCA;SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGK;TCCTATGAGCTGACTCAGGAGACTGGTGTCTCTGTGGCCCTGGGACGGACAGTCACAATCACGTGCCGGGGAGACAGCCTCAGAAGTCATTATGCAAGTTGGTACCAAAAGAAGCCAGGACAGGCCCCTATACTTCTCTTCTATGGTAAAAATAATCGTCCTTCAGGGGTCCCAGACCGATTCTCTGGCTCCGCCTCAGGAAACAGAGCTTCCTTGACCATCTCTGGGGCTCAGGCGGAAGACGACGCGGAATATTATTGTAGTTCTCGGGACAAGAGTGGCAGCCGTCTGTCGGTCTTCGGCGGGGGGACCAAACTGACCGTCCTCA;237.574680299113
12A12;gp120 CD4BS;;12 ;12A12;Scheid2011(21764753) ;12A12 signature predictions (West2013),hypervariable loop characteristic correlations with bNAb sensitivity,Signature Analysis Summary;Scheid2011(21764753) ;;IGHV1-2;IGHD1-26,IGHD3-10;IGHJ4,IGHJ5;13.0;DGSGDDTSWHLDP;IGKV1D-33;IGKJ3;5.0;AVLEF;K;12A12 d57; ;SQHLVQSGTQVKKPGASVRISCQASGYSFTDYVLHWWRQAPGQGLEWMGW;TCCCAGCATTTGGTGCAATCTGGGACTCAGGTGAAGAAGCCTGGGGCCTCAGTGAGGATCTCATGCCAGGCTTCTGGATACAGCTTCACCGACTACGTTCTCCACTGGTGGCGACAGGCCCCAGGCCAAGGGCTGGAGTGGATGGGGTGGATCAAGCCTGTCTACGGTGCCAGAAACTACGCGCGCAGGTTTCAGGGCAGGATAAACTTTGATCGGGACATCTACAGGGAGATAGCCTTCATGGACTTGAGTGGACTGAGATCTGACGACACGGCCCTATATTTTTGTGCGAGAGATGGGAGCGGGGACGACACCTCTTGGCACTTAGATCCCTGGGGCCAGGGAACGCTGGTCATTGTCTCCGCAGCGTCGACCAAGGGCC;DIQMTQSPSSLSASVGDRVTITCQAGQGIGSSLQWYQQKPGKAPKLLVHG;GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGAGACAGAGTCACCATCACCTGCCAGGCGGGTCAGGGCATTGGCTCCTCTCTACAGTGGTATCAACAAAAACCAGGGAAAGCCCCTAAGCTCCTGGTCCACGGCGCTTCCAACTTACACAGAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATTCCACACAACTTTCAGTCTCACCATCAGCGGCCTACAGCGTGACGATTTTGCGACATACTTCTGTGCGGTACTTGAATTCTTCGGCCCCGGGACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGT;253.670142263096
179NC75;gp120 CD4BS;;EB179 ;;Freund2015(26516768) ;179NC75 binding-associated sites;Freund2015(26516768) ;IgBlast IMGT/V-QUEST;IGHV3-21;IGHD3-9;IGHJ5;24.0;VHAWRYFDWVNRRSPVEKVLSIDL;IGLV3-1;IGLJ2;10.0;QTWDSKNYVT;L;; ;;CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATCCATTAGTAGTAGTAGTAGTTACATATACTACGCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGTCCATGCTTGGCGATATTTTGACTGGGTTAATCGGAGAAGTCCTGTGGAGAAGGTCTTGTCTATAGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCGTCGACTTCGCA;;CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCAGCATCACCTGCTCTGGAGATAAATTGGGGGATAAATATGCTTGCTGGTATCAGCAGAAGCCAGGCCAGTCCCCTGTGCTGGTCATCTATCAAGATAGCAAGCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACAGCCACTCTGACCATCAGCGGGACCCAGGCTATGGATGAGGCTGACTATTACTGTCAGGCGTGGGACAGCAAGAATTATGTGACTTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCGAGTGAGGAG;91.5558965339497
17b;gp120 CD4i CoRBS (Cluster C);1RZ8(antibody 17b),1YYL(CD4M33, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b),2I5Y(CD4M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b),1YYM(F23, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b),1GC1(gp120 core complexed with CD4 and 17b),1RZJ(gp120 (HXB2) complexed with CD4 and 17b),1G9M(gp120 (HXB2) complexed with CD4 and 17b),2NY1(gp120 (I109C, T257S, S334A, S375W, Q428C) complexed with CD4 and 17b),2NY3(gp120 (K231C, T257S, E267C, S334A, S375W) complexed with CD4 and 17b),2NY4(gp120 (K231C, T257S, E268C, S334A, S375W) complexed with CD4 and 17b),2NY6(gp120 (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) complexed with CD4 and 17b),2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b),2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b),2NXY(gp120 (S334A) complexed with CD4 and 17b),2NY2(gp120 (T123C, T257S, S334A, S375W, G431C) complexed with CD4 and 17b),2NXZ(gp120 (T257S, S334A, S375W) complexed with CD4 and 17b),1RZK(gp120 (YU2) complexed with CD4 and 17b),1G9N(gp120 (YU2) complexed with CD4 and 17b),4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab),2I60([Phe23]M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);N70 ;;;17b contacts,MPER membrane fusion mutations (Fu2018),Mutation affects binding to 17b and 412d,Mutation affects neutralization;Gorny2009(18952295) ;;IGHV1-69;;IGHJ1;;;;;;;K;1.7b, 1.7B, sCD4-17b; ;EVQLVESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGR;ACCGGTGTCCAGTGTCAGGTGCAGCTGCTCGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCCTCTGGAGACACCTTCATCAGATATAGTTTTACCTGGGTGCGACAGGCCCCTGGACAAGGCCTTGAGTGGATGGGAAGGATCATCACTATCCTTGATGTAGCACACTACGCACCGCACCTCCAGGGCAGAGTCACGATTACCGCGGACAAGTCCACGAGCACAGTCTACCTGGAGCTGCGGAATCTAAGATCTGACGATACGGCCGTATATTTCTGTGCGGGAGTGTACGAGGGAGAGGCGGACGAGGGGGAATATGATAATAATGGGTTTCTGAAACATTGGGGCCAGGGAACCCTGGTCACGGTCACCTCAGCGTCGAC;DIVMTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYG;ACCGGTACCACCGGAGAACTCGAGTTGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTGAGAGTGTTAGTAGCGACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATATATGGTGCATCCACCAGGGCCACCGGTGTCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGGCAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACAATAACTGGCCTCCGAGGTACACTTTTGGCCAGGGGACCAGGCTGGAGATCAAACGTACG;0.0
1B2530;gp120 CD4BS;4YFL(1B2530 in complex with HIV-1 clade AE 93TH057 gp120);1 ;;Scheid2011(21764753) ;1B2530 contacts,Signature Analysis Summary;Scheid2011(21764753) ;;IGHV1-46;IGHD6-13,IGHD6-19;IGHJ4,IGHJ5;16.0;AEAASDSHSRPIMFDH;IGLV1-47;IGLJ3;11.0;ATYDSDGSIRL;L;; 1B2530 is a close clonal relative to INC127, and the germline repertoir is as shown for INC127 in Scheid2011.;QVQLEQSGTAVRKPGASVTLSCQASGYNFVKYIIHWVRQKPGLGFEWVGM;CAGGTGCAGCTGGAACAATCGGGGACTGCGGTGAGGAAGCCTGGGGCCTCGGTGACGCTTTCCTGCCAGGCGTCCGGTTACAACTTCGTCAAATACATCATTCACTGGGTGCGCCAGAAACCTGGACTCGGCTTTGAGTGGGTTGGCATGATCGACCCCTACCGTGGCCGGCCATGGTCCGCGCACAAATTTCAGGGTCGACTCTCCCTGAGTCGAGACACTTCCATGGAAATACTATATATGACCCTGACCAGCCTGAAATCTGACGACACGGCCACCTATTTCTGTGCGAGGGCTGAGGCAGCATCCGACAGTCATTCTCGACCCATCATGTTCGACCACTGGGGCCAGGGCTCCCTGGTCACCGTCTCCTCAGCGTCGACCAAGGGCCCATCGGTCTTC;QSALTQPPSASGAPGQRVTISCSGGPSNVGGNYVYWYRQFPGTAPTLLIL;CAGTCTGCCCTGACTCAGCCACCCTCAGCGTCTGGGGCCCCCGGGCAGAGGGTCACCATCTCCTGTTCCGGAGGTCCCTCCAACGTCGGCGGCAATTATGTCTACTGGTATCGGCAGTTTCCAGGCACGGCCCCCACGCTCCTCATCCTTCGAGATGACCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCCGCGTCTAAGTCTGGCAATTCAGCCTCCCTGGCCATCAGTGGGCTCCGACCGGACGATGAGGGTTTTTATTTCTGTGCAACATATGATAGTGACGGAAGTATTCGACTGTTCGGCGGAGGAACCGCATTAACTGTCCTGAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCC;82.7579066100075
2F5;gp41 MPER (membrane proximal external region);1TJG(2F5 complexed with gp41 7mer epitope),2F5B(2F5 complexed with gp41 epitope),2PR4(2F5 Fab),3BQU(2F5 Fab-3H6 Fab Complex),3MOB(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide),3MOD(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide),3MOA(2F5 Fab fragment with 17 aa gp41 MPER-derived peptide),3IDI(2F5 Fab fragment with gp41 Peptide ALDKWNQ),3IDM(2F5 Fab fragment with gp41 Peptide analog ELD(Nrg)WAS),3IDJ(2F5 Fab fragment with gp41 Peptide analog ELD(Orn)WAS),3IDN(2F5 Fab fragment with gp41 Peptide analog ELD(Paf)WAS),1TJH(2F5 with a gp41 11mer epitope),1TJI(2F5 with a gp41 17mer epitope),3LEV(2F5 with epitope scaffold ES2),3D0L(2F5 with gp41 FP-MPER Hyb3K construct),3DRQ(2F5 with gp41 FP-MPER Hyb3K construct soaked in PEG/2-propanol),1U8H(2F5 with gp41 Peptide ALDKWAS),3IDG(2F5 with gp41 Peptide ALDKWD),1U92(2F5 with gp41 Peptide Analog E-[Dap]-DKWQS (cyclic)),1U91(2F5 with gp41 Peptide Analog ENDKW-[Dap]-S (cyclic)),1U8P(2F5 with gp41 Peptide ECDKWCS),1U8O(2F5 with gp41 Peptide ELDKHAS),1U8J(2F5 with gp41 Peptide ELDKWAG),1U8I(2F5 with gp41 Peptide ELDKWAN),2PW2(2F5 with gp41 Peptide ELDKWKSL),2PW1(2F5 with gp41 Peptide ELDKWNSL),1U8Q(2F5 with gp41 Peptide ELEKWAS),3DRO(2F5 with gp41 peptide ELLELDKWASLWN),2P8L(2F5 with gp41 Peptide ELLELDKWASLWN),2P8M(2F5 with gp41 Peptide ELLELDKWASLWN in new crystal form),2P8P(2F5 with gp41 Peptide LELDKWASLW[N-Ac]),3D0V(2F5 with gp41 Peptide LLELDKWASLW),3DRT(2F5 with gp41 scrambledFP-MPER scrHyb3K construct),3EGS(2F5 with gp41 scrambledFP-MPER scrHyb3K construct soaked in ammonium sulfate),2F5A(Fab 2F5);;2F5;Buchacher1994(7520721) ;2F5 contacts,2F5 signature predictions (West2013),hypervariable loop characteristic correlations with bNAb sensitivity,Mutation affects 2F5 binding,Signature Analysis Summary;Kunert1998(9737583) ;;IGHV2;;IGHJ6;;;;;;;K;c2F5, IAM 2F5, IAM2F5, IAM-41-2F5; ;RITLKESGPPLVKPTQTLTLTCSFSGFSLSDFGVGVGWIRQPPGKALEWL;AGGATCACGTTAAAGGAATCGGGTCCTCCGCTGGTGAAACCCACACAGACTCTCACGCTGACCTGTTCCTTCTCTGGGTTCTCACTGTCCGATTTTGGAGTGGGTGTAGGCTGGATCCGTCAGCCCCCAGGAAAGGCCCTAGAGTGGCTTGCAATCATTTATTCGGATGATGATAAGCGCTACAGCCCATCGCTGAACACCAGACTCACCATCACCAAGGACACCTCCAAAAATCAAGTTGTCCTTGTCATGACTAGGGTGAGTCCTGTGGACACAGCCACGTATTTCTGTGCACAC;ALQLTQSPSSLSASVGDRITITCRASQGVTSALAWYRQKPGSPPQLLIYD;GCCCTCCAACTGACCCAGTCTCCGTCCTCCTTGTCTGCATCTGTTGGAGACAGAATCACCATCACTTGTCGGGCAAGTCAGGGCGTTACCAGTGCTTTAGCCTGGTATCGACAGAAGCCAGGAAGTCCTCCTCAACTCCTAATCTATGATGCCTCCTCTTTAGAAAGTGGGGTCCCATCGAGGTTCAGCGGCAGTGGTTCTGGGACGGAGTTCACTCTCACCATCAGCACCCTGCGGCCTGAAGATTTTGCAACTTATTACTGTCAACAATTACATTTTTACCCT;83.3405126424462
2G12;gp120 carbohydrates at glycosylation residues in C2, C3, C4, and V4,gp120 V3 // V3 glycan (V3g);4RBP(2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomanose),3OAU(2G12 Recognizes Di-Mannose),1OM3(Fab 2G12),1OP3(Fab 2G12 bound to disaccharide mannose),1OP5(Fab 2G12 bound to oligosaccharide mannose),1ZLS(Fab 2G12 + Man4),1ZLU(Fab 2G12 + Man5),1ZLV(Fab 2G12 + Man7),1ZLW(Fab 2G12 + Man8),2OQJ(Fab 2G12 with 21-mer peptide ligand),3OB0(Mimic of the HIV glycan shield),3OAY(Mimic of the HIV glycan shield),3OAZ(Mimic of the HIV glycan shield);;2G12;Buchacher1994(7520721) ;2G12 contacts,2G12 signature predictions (West2013),BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs,Mutation affects 2G12 binding;Huber2010(20702640) ;IMGT/V-QUEST;IGHV3-21;IGHD6-25;IGHJ3;;;IGKV1-5;IGKJ1;;;K;c2G12; ;EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVAS;GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGGCGGGAGGATCCCTCATACTCTCCTGTGGAGTCTCTAATTTTAGAATCTCTGCCCATACCATGAATTGGGTCCGCCGGGTTCCAGGGGGGGGGCTGGAGTGGGTCGCTTCCATTAGTACGAGTTCCACTTATAGAGACTATGCAGACGCTGTGAAGGGCCGATTCACCGTTTCCAGAGACGACCTCGAAGACTTTGTGTATTTGCAAATGCACAAAATGAGAGTCGAAGACACGGCTATTTATTACTGCGCCAGA;DIQMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYK;GACATCCAGATGACTCAGTCTCCTTCCACCCTGTCTGCATCTGTCGGAGACACAATCACCATCACTTGCCGGGCCAGTCAGAGTATTGAAACCTGGTTGGCCTGGTATCAGCAGAAGCCAGGGAAAGCCCCAAAACTCCTAATCTACAAGGCGTCTACTTTAAAAACTGGAGTCCCGTCAAGATTCAGCGGCAGTGGATCTGGAACAGAGTTCACTCTTACCATCAGTGGCCTGCAGTTCGATGACTTTGCAACTTATCACTGTCAGCACTATGCTGGTTATTCA;32.1343561976123
3074;gp120 V3 // V3 glycan (V3g);3MLX(Fab 3074 in complex with an MN V3 peptide),3MLY(Fab 3074 in complex with a UR29 V3 peptide),3MLZ(Fab 3074 in complex with a VI191 V3 peptide);;;Gorny2006(16809292) ;;Andrabi2013(23466102) ;IMGT/V-QUEST;IGHV4-59*01;;IGHJ3*01;;ARDFGEYHYDGRGFQCEGFDL;IGLV1-51*02;IGLJ2*01,IGLJ3*01;;ATWDGSLRTV;L;V3-3074; ;QVQLQESGPGLVKPSETLSLTCTVSGGSISGFHWSWIRQPPGKGLEYIGY;CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACTTGCACTGTCTCTGGTGGCTCCATCAGTGGTTTCCACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTACATTGGCTATATCTATTACAGTGGGTCCACCAGCTACAACCCCTCCCTCAAGAGTCGAGTCAGTATGTCAGTAGACACGTCCCGGAACCAGTTCTCCCTGGAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTCTATTACTGTGCGAGAGATTTTGGGGAATATCACTATGATGGTCGTGGCTTCCAGTGTGAGGGTTTTGATCTCTGGGGCCAAGGGACACTGGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC;;;15.8366518720061
35O22;gp41-gp41 interface;4TOY(35O22 Fab),6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22),6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22),6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22),5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22),5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01),4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22),5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);N152 ;35O22;Huang2014(25186731) ;35O22 contacts and mutagenesis,Sites affecting neutralization of 35O22;Huang2014(25186731) ;IMGT/V-QUEST;IGHV1-18*02;IGHD5-24*01;IGHJ4*03,IGHJ4*02;16.0;GLLRDGSSTWLPYL;IGLV2-14*02,IGLV2-23*03,IGLV2-23*02,IGLV2-23*01;IGLJ1*01;10.0;CSYTHNSGCV;L;; ;QGQLVQSGAELKKPGASVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGW;CAGGGTCAACTAGTCCAGTCTGGAGCTGAATTGAAAAAGCCTGGCGCCTCGGTGAAGATTTCCTGTAAGACTTCGGGTTATAGGTTTAATTTCTATCATATTAATTGGATTCGACAAACTGCAGGACGTGGACCTGAGTGGATGGGATGGATCAGCCCTTACAGTGGTGACAAAAACCTCGCACCTGCCTTTCAAGACAGAGTCATTATGACGACAGACACAGAAGTCCCTGTGACCTCATTCACGTCCACGGGCGCAGCCTACATGGAAATAAGGAACCTGAAATTTGACGACACAGGCACCTATTTCTGTGCAAAAGGCCTCCTGCGTGACGGTTCGTCGACGTGGCTTCCTTATTTGTGGGGCCAGGGTACCCTACTCACCGTCTCGTCA;QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLII;CAGTCTGTGCTGACGCAGTCTGCCTCCGTGTCTGGGTCTCTTGGACAGTCGGTCACCATCTCCTGCACTGGACCCAATAGTGTTTGTTGCAGTCACAAATCTATCTCCTGGTATCAGTGGCCCCCAGGCAGAGCCCCCACACTCATCATTTATGAGGACAATGAAAGGGCCCCGGGAATCTCTCCTCGCTTCTCTGGCTACAAGTCGTATTGGTCGGCCTACTTGACAATCTCTGATCTCCGGCCTGAAGACGAGACCACTTACTACTGTTGCTCATACACTCACAATAGCGGCTGTGTCTTCGGGACTGGGACCAAGGTCTCCGTCTTG;142.402947859267
3BNC117;gp120 CD4BS;4JPV(3BNC117 complexed with gp120),4LSV(3BNC117 complexed with gp120 (C1086));3 ;3BNC117;Scheid2011(21764753) ;3BNC117 alanine scanning,3BNC117 contacts,3BNC117 signature predictions (West2013),hypervariable loop characteristic correlations with bNAb sensitivity,Signature Analysis Summary,Sites selected during 3BNC117 immunotherapy;Scheid2011(21764753) ;;IGHV1-2;IGHD6-25,IGHD2-8;IGHJ2,IGHJ6;10.0;QRSDYWDFDV;IGKV1D-33;IGKJ3;5.0;QVYEF;K;3BNC117 dRU3; ;QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGW;CAGGTCCAATTGTTACAGTCTGGGGCAGCGGTGACGAAGCCCGGGGCCTCAGTGAGAGTCTCCTGCGAGGCTTCTGGATACAACATTCGTGACTACTTTATTCATTGGTGGCGACAGGCCCCAGGACAGGGCCTTCAGTGGGTGGGATGGATCAATCCTAAGACAGGTCAGCCAAACAATCCTCGTCAATTTCAGGGTAGAGTCAGTCTGACTCGACACGCGTCGTGGGACTTTGACACATTTTCCTTTTACATGGACCTGAAGGCACTAAGATCGGACGACACGGCCGTTTATTTCTGTGCGCGACAGCGCAGCGACTATTGGGATTTCGACGTCTGGGGCAGTGGAACCCAGGTCACTGTCTCGTCAGCGTCGACCAAGGGCCCA;DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKL;GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCCTCTGTGGGAGATACCGTCACTATCACTTGCCAGGCAAACGGCTACTTAAATTGGTATCAACAGAGGCGAGGGAAAGCCCCAAAACTCCTGATCTACGATGGGTCCAAATTGGAAAGAGGGGTCCCATCAAGGTTCAGTGGAAGAAGATGGGGGCAAGAATATAATCTGACCATCAACAATCTGCAGCCCGAAGACATTGCAACATATTTTTGTCAAGTGTATGAGTTTGTCGTCCCTGGGACCAGACTGGATTTGAAACGTACGGTGGCTGCACCA;269.109024710939
447-52D;gp120 V3 // V3 glycan (V3g);3C2A(447-52D in complex with UG1033 peptide),1Q1J(Fab 447-52D in complex with V3 peptide),3GHB(Fab 447-52D in complex with V3 peptide 92RW020),4M1D(Fab 447-52D with V3 cyclic peptide MN);;;Buchbinder1992(1466965) ;Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs;;;;;;;;;;;;L;447, 447-52-D, 447/52-DII, 447d, 447-D, 447D, 447D-52; ;QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVLWYQQFPGTAPKLLIY;GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTCAGACTCACCTGTGTAGCCTCTGGTTTCACGTTCAGTGATGTCTGGCTGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCGGCCGTATTAAAAGCAGAACTGATGGTGGGACAACAGACTACGCTGCATCCGTGAAAGGCAGATTCACCATCTCAAGAGATGACTCAAAAAACACGCTATATCTGCAAATGAATAGCCTGAAAACCGAGGACACAGCCGTTTATTCCTGCACCACAGATGGTTTTATTATGATTCGGGGAGTCTCCGAGGACTACTACTACTACTACATGGACGTTTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA;EVQLVESGGGLVKPGGSLRLTCVASGFTFSDVWLNWVRQAPGKGLEWVGR;CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGAATAATTATGTATTGTGGTACCAGCAGTTCCCAGGAACAGCCCCCAAACTCCTCATTTATGGCAATAATAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTTCTGCGCAACATGGGATAGCGGCCTGAGTGCTGATTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAAGT;10.4343547164339
48d;gp120 CD4i;1RZ7(Human anti-HIV-1 GP120-reactive antibody 48d),4DVR(YU2 gp120 core in complex with Fab 48d and NBD-557);;;;;Gorny2009(18952295) ;;IGHV1-f*01;IGHD1-26;IGHJ3;;;;;;;K;48D, 4.8d, 4.8D; ;EVQLVQSGAEVKKPGATVKISCKASGYTFSDFYMYWVRQAPGKGLEWMGL;GAGGTCCAGCTGGTACAGTCCGGGGCTGAGGTGAAGAAGCCTGGGGCCACCGTGAAGATCTCCTGCAAGGCTTCTGGATACACCTTCAGCGACTTCTACATGTACTGGGTGCGACAGGCCCCTGGGAAAGGGCTTGAGTGGATGGGCCTTATTGATCCTGAAGATGCTGATACAATGTATGCAGAGAAGTTCCGGGGCAGAGTCACCATAACCGCAGACACGTCTACAGACACAGGCTATTTGGAACTGAGCAGCCTGAGATCTGAGGACACGGCCGTCTATTACTGTGCAGCAGATCCGTGGGAACTAAATGCATTTAATGTCTGGGGCCAAGGGACACTGGTCAGCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAG;DIQMTQSPSSVSASVGDRVTITCRASQDISTWLAWYQQKPGKAPKLLIYA;GACATCCAGATGACCCAGTCTCCATCTTCTGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGATATTAGCACCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATATATGCTGCATCCACTTTGCAAAGTGGTGTCCCGTCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCAGTCTCACTATCAACAGCCTGCAGCCTGAGGATTTTGCGACTTACTATTGTCAACAGGCTAACAGTTTCTTCACATTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAACTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTGACCAAGAGCTTCAACAGGGGCGAG;0.0
4E10;gp41 MPER (membrane proximal external region);4XCE(4E10 Fab crystalized in the presence of Phosphatidylcholine, C2 space group),4XCC(4E10 Fab crystalized in the presence of Phosphatidylcholine, I422 space group),4XBP(4E10 Fab crystalized in the presence of Phosphatidylethanolamine),4NHC(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41),4NGH(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety),4XAW(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid),4XCF(4E10 Fab in complex with its peptide epitope on HIV-1 gp41, crystals cryoprotected with phosphatidylcholine),4XC3(4E10 Fab in complex with its peptide epitope on HIV-1 gp41, crystals cryoprotected with rac-glycerol 1-phosphate),4XC1(4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate),4XBE(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin),4XBG(4E10 Fab in complex with phosphatidic acid: 2.73 A resolution),4XCN(4E10 Fab in complex with phosphatidic acid, 2.9 A resolution),4XCY(4E10 Fab in complex with phosphatidylglycerol),4ODX(4E10 germline encoded precursor no.7 in complex with epitope scaffold T117),3H3P(Epitope-scaffold 4E10 Fv complex),1TZG(Fab 4E10 complexed with gp41 13mer epitope),2FX8(Fab 4E10 complexed with gp41 Aib-induced peptide),2FX7(Fab 4E10 complexed with gp41 epitope),2FX9(Fab 4e10 with 4e10 epitope on gp41),5CIN(non-neutralizing version of 4E10 (DeltaLoop) with epitope bound),5CIL(non-neutralizing version of 4E10 (WDWD) with epitope bound),4M62(Ontogeny of recognition specificity and functionality for 4E10),4M8Q(Ontogeny of recognition specificity and functionality for 4E10),4LRN(Ontogeny of recognition specificity and functionality for 4E10),4OB5(Ontogeny of recognition specificity and functionality for 4E10),4WY7(recombinant 4E10 expressed in Escherichia coli with epitope bound),5CIP(Unbound 4E10),4LLV(Unbound form of 4E10 Fv);;4E10;Buchacher1994(7520721) ;4E10 contacts,4E10 signature predictions (West2013),hypervariable loop characteristic correlations with bNAb sensitivity,Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs,Mutation affects 4E10 binding,Mutation affects neutralization,Signature Analysis Summary;Kunert2004(15307922) ;;IGHV1-69;IGHD3-16,IGHD6-19;;;;IGKVA27;;;;K;; ;GSQVQLVQSGAEVKRPGSSVTVSCKASGGSFSTYALSWVRQAPGRGLEWM;ACCGGTGTCCAGTGTCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTGACGGTCTCCTGCAAGGCTTCTGGAGGCTCCTTCAGCACTTATGCTCTCAGCTGGGTGCGACAGGCCCCTGGACGAGGGCTTGAATGGATGGGAGGGGTCATCCCTCTATTGACCATAACAAATTATGCCCCAAGATTCCAGGGCAGAATCACAATTACCGCGGACAGATCCACGAGCACGGCCTACCTGGAATTGAACAGCCTGCGACCTGAAGACACGGCCGTCTATTATTGTGCGAGAGAAGGGACTACTGGCTGGGGCTGGCTGGGCAAACCCATAGGGGCGTTTGCCCACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCGTCGAC;EIVLTQSPGTQSLSPGERATLSCRASQSVGNNKLAWYQQRPGQAPRLLIY;ACCGGTGCCAAATGTGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGTGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGGCAATAATAAGTTAGCCTGGTATCAGCAGAGACCCGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGCCCTCTGGCGTCGCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGTAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTCAGTCTTTATCCACGTTCGGCCAAGGGACCAAGGTAGAAGTCAAACGTACG;183.19608100519
561_01_18;gp120 CD4BS;;IDC561 ;;Schommers2020(32004464) ;;;;;;;;;;;;;K;1-18; ;;CAGGGTCGTTTGTTTCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGGCCTCAGTGAGGATTTCTTGTCGGGCAGACGACGACCCCTACACCGACGACGACACCTTCACCAAATACTGGACACACTGGATTCGACAGGCCCCTGGACAGCGACCTGAGTGGCTGGGGGTCATCAGCCCTCACTTTGCTCGGCCCATTTACTCATATAAGTTCCGAGACAGACTCACGCTGACCAGGGACTCGTCCCTGACAGCCGTCTATTTGGAACTTAAAGGTCTGCAACCTGACGACTCGGGCATTTACTTCTGTGCGCGAGATCCGTTCGGGGACAGGGCCCCCCACTATAACTATCACATGGACGTCTGGGGCGGAGGGACCGCGGTCATCGTCTCCTCT;;GAAGTTGTGTTGACACAGTCTCCAGCCATCCTCTCTGTGTCTCCGGGGGACAGAGTCATCCTCTCCTGTAGGGCCAGTCAGGGTCTTGATTCCAGCCACCTCGCCTGGTATCGGTTCAAACGTGGCCAGATTCCCACACTCGTCATCTTTGGTACTTCCAATAGGGCCAGAGGCACCCCAGACCGTTTCAGTGGCAGTGGGTCTGGGGCAGACTTCACCCTCACTATTAGCAGGGTGGAACCTGAAGATTTCGCTACTTATTACTGTCAGCGATATGGCGGCACGCCCATCACATTCGGCGGCGGGACCACATTGGACAAAAAA;315.284098865018
561_01_55;gp120 CD4BS;;IDC561 ;;Schommers2020(32004464) ;;;;;;;;;;;;;K;1-55; ;;CAGCGTCGTTTGTTTCAGTCTGGGACTGAGGTGAAGAGGCCTGGGGCCTCAGTGAAGATTTCTTGTCGGGCAGACGACGACCCCTACACCGACGACGACACATTCACCAAATACTATACACACTGGATTCGACAGGCCCCTGGACAGCCACCTGAGTGGCTGGGGGTCATCAGCCCTCACTTTGCTCGGCCGATTTACTCATATAAGTTCCGAGACAGACTCACGCTGACCAGGGACTCGTCCCTGACAGCCGTCTATTTCGAACTTAGAGGTCTGCAACCTGACGACACGGGCATTTACTTCTGTGCGCGAGATCCCTTCGGGGACATGTACCCCCACTACAACTACCACATGGACGTCTGGGGCGGAGGGACCACAGTCATCGTCTCCGCA;;GAGGCTGTGTTGACACAGTCTCCAGCCATCCTCTCTGTGTCTCCGGGAGACAGAGTCATCCTCTCCTGTAAGGCCAGTGAGGGTCTTAGCTCCAGTGACCTGGCCTGGTATCGATTCAAAGGTGGCCAGATTCCCACTCTCGTCATCTTTGGTGCGTCCAATAGGGCCAGAGGCACCCCAGACCGTTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCACTATCAACAGGGTGGAACCTGAAGATTTCGCTACATATTACTGTCAACGATATGGCGGCACGCCCATCACATTCGGCGGCGGGACCACATTGGACAAAAAA;267.638707017385
561_02_12;gp120 CD4BS;;IDC561 ;;Schommers2020(32004464) ;;;;;;;;;;;;;K;2-12; ;;CAATTAGTGCAGTCTGGCGGTGGGGTGAGGAGGCCTGGGGCCTCAGTGAAAATTTCCTGTGAGACACCAGAAGACACCTTCACTAAATACTGGCTTCACTGGCTGCGACAGGCCCCTGGGCAAGGACTTGAGTGGATGGGGGTTGTTAGCCCTCATGGTGGAAGGCCGATGTTCGCATTTGAGTTTCGGGACAGGCTCACTCTGACGAGGGACATTCACACGACAACACATTTTATGGAACTGAGAGGCCTAACCTCAGACGATACGGCCGTATATTATTGTGCCAGAGATCCCTTTGGGGAGACATTTCGCGGTCACGACCAGCCCTATCGGATGGACGTCTGGGGCGGAGGGACCACAATCGTCGTCTCCTCA;;GAACCTGTCTTGACACAGTCTCCAGGCACCCTGTCTGTGTCTCCGGGGGAAGGAGCCACCCTCTCTTGCAGGGCCAGGCAGGGCTTCAGCGCCGATCACGTAGCCTGGTTTCAGAAAAAACCTGGCCGGCCTCCCAGACTCCTCATATTTGAGGCGTCTAGGAGGGCCAGTGGCACCCCAGAGCGGTTCAGTGGCAGTGGGTCTGGGCCCGAATACACTCTCACCATCACCCGTGTGGAAGCTGAAGATTTTGCGGTCTATTACTGCCAGTCATATGGCTCCATCACACCATTGGTTTTCGGCGGAGGGACCAGGGTGGACGTCAAA;281.156472338625
8ANC131;gp120 CD4BS;4RWY(8ANC131 in complex with HIV-1 clade B YU2 gp120);8 ;;Scheid2011(21764753) ;8ANC131 contacts,hypervariable loop characteristic correlations with bNAb sensitivity,Signature Analysis Summary;Scheid2011(21764753) ;;IGHV1-46;IGHD3-16;IGHJ6;16.0;DGLGEVAPDYRYGIDV;IGKV3-11;IGKJ2,IGKJ3;9.0;QEYSSTPYN;K;; ;QGQLVQSGGGLKKPGTSVTISCLASEYTFNEFVIHWIRQAPGQGPLWLGL;CAGGGGCAGTTGGTGCAGTCCGGGGGTGGACTGAAGAAACCTGGGACGTCAGTGACGATTTCCTGCCTGGCATCTGAATACACATTCAACGAATTCGTTATTCACTGGATTCGACAGGCCCCTGGACAGGGGCCTCTGTGGCTGGGTCTAATCAAACGTAGCGGTCGTTTGATGACTGCCTATAATTTTCAAGACAGACTCAGTCTGCGAAGAGACCGTTCGACGGGAACAGTCTTCATGGAGTTGCGGGGTCTCAGACCTGACGACACGGCCGTGTATTATTGTGCGAGGGATGGATTGGGGGAGGTAGCGCCGGACTATCGTTACGGCATTGACGTCTGGGGTCAGGGGTCCACGGTCATCGTCACCTCAGCGTCGACCAAGGGCCCATCGGTCTTCCC;EIVLTQSPATLSLSPGERATLSCRASQGLNFVVWYQQKRGQAPRLLIHAP;GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTCTGTCTCCAGGGGAAAGAGCCACCCTTTCCTGCAGGGCCAGTCAGGGTCTGAACTTCGTAGTCTGGTATCAACAAAAACGTGGGCAGGCTCCCAGACTTCTCATCCACGCTCCTTCTGGTAGGGCCCCTGGCGTCCCAGACAGATTCAGTGCCCGGGGGTCCGGGACAGAGTTCTCTCTCGTCATTAGTTCGGTGGAGCCTGATGATTTCGCAATATATTACTGTCAAGAATATAGTTCGACACCATACAACTTTGGCCCCGGGACCAGAGTGGATCGCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGT;126.087563809892
8ANC195;gp41-gp120 interface;4P9M(8ANC195 Fab),5CJX(8ANC195 Fab in complex with BG505 SOSIP.664 HIV-1 Env trimer),4P9H(8ANC195 Fab in complex with gp120 of 93TH057 HIV-1 and soluble CD4 D1D2),5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195),5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195),5A8H(cryo-ET subtomogram averaging of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195),5A7X(negative stain EM of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);8 ;;Scheid2011(21764753) ;8ANC195 contacts,8ANC195 contacts,8ANC195 residue prediction,8ANC195 signature predictions (West2013),Signature Analysis Summary;Scheid2011(21764753) ;;IGHV1-69;IGHD3-3;;20.0;TSTYDQWSGLHHDGVMAFSS;IGKV1-5;IGKJ1,IGKJ5;9.0;QQYDTYPGT;K;; 8ANC195 is a close clonal relative of 8ANC142, and the repertoir is shown for 8ANC142 in Scheid2011.;QIHLVQSGTEVKKPGSSVTVSCKAYGVNTFGLYAVNWVRQAPGQSLEYIG;CAGATACACCTCGTACAATCTGGGACCGAAGTCAAGAAGCCTGGGTCCTCGGTGACGGTCTCCTGCAAGGCCTATGGAGTCAACACTTTCGGTCTCTATGCCGTCAATTGGGTGCGACAGGCCCCAGGACAAAGTCTTGAGTACATAGGACAGATATGGCGGTGGAAATCCAGCGCTTCACATCATTTCCGGGGCCGAGTCCTCATTTCCGCGGTGGACCTCACGGGCTCCTCGCCGCCTATTTCTTCCTTGGAGATCAAGAACCTGACCTCTGACGACACGGCCGTCTATTTTTGCACGACAACCTCGACGTACGACAAGTGGAGTGGCCTTCATCACGACGGGGTCATGGCATTTTCCTCTTGGGGCCAGGGAACCCTCATCTCCGTCTCCGCGGCGTCGACCAAGGGCCCATCGGTCTTC;DIQMTQSPSTLSASIGDTVRISCRASQSITGNWVAWYQQRPGKAPRLLIY;GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTATAGGTGACACAGTCAGGATCTCTTGCCGGGCCAGCCAGAGTATCACTGGTAACTGGGTGGCGTGGTATCAGCAGAGACCAGGGAAAGCCCCTAGACTCCTCATTTATAGGGGAGCCGCATTACTAGGTGGGGTCCCGTCAAGGTTCAGCGGCAGTGCAGCTGGGACAGACTTCACTCTCACCATCGGCAACCTGCAGGCTGAAGATTTTGGAACTTTTTACTGCCAACAGTATGACACTTATCCAGGGACCTTCGGCCAAGGGACTAAAGTTGAGGTGAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT;125.980796516374
BG1;gp120 V1-V2;5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195);EB354 ;;Freund2017(28100831) ;;Freund2017(28100831) ;IMGT/V-QUEST;IGHV3-49;;;22.0;EQRNKDYRYGQEGFGYSYGMDV;IGKV1-39;;;;K;354BG1; ;;GCGGAACAATTAGTGGAATCTGGGGGAGGCCTGGTCCCGCCAGGGCGGTCCCTGCGGCTTTCCTGTTCAGCCTCTGGCTTCTACTTTCCTGATTATGCCATGGCCTGGGTCCGACAGGCTCCAGGGCAGGGGCTCCAATGGGTCGGTTTTATGAGAGGCTGGGCCTATGGTGGCTCAGCCCAATTTGCCGCATTTGCGGTCGGAAAATTCGCAATTTCGAGAGACGACGGCAGAAATGTCGTCTACCTGGATGTGAAGAACCCCACTTTCGAAGACACGGGCGTCTATTTTTGTGCCAGGGAACAACGGAACAAAGACTACCGTTATGGCCAGGAGGGCTTCGGCTATTCTTACGGCATGGACGTTTGGGGCCGAGGGACCACGGTCGTCGTCTCCACA;;GACATCCATATGACCCAGTCTCCAGTCTCCCTGTCTGCATCTGTCGGAGACAGAGTCACAATCACTTGCCGGGCAAGTCACTTCATTGCAAATTATGTCAATTGGTATCAACAAAAACCAGGCAAAGCCCCGACACTCCTCATTTTTGAATCGTCGACGTTACAGAGAGGGGTCCCATCGAGGTTCTCTGCCTATGGAGACGGGACAGAGTTCACTCTCTCTATCAACACTCTCCAGCCTGAAGATTTTGCATCTTACATCTGTCAACAGAGTCACAGTCCTCCTGTCACTTTTGGTGCGGGGACGCGGGTCGACCAGAAA;93.9009736703237
BG18;gp120 V3 // V3 glycan (V3g);6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22),6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22),6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22),6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA);EB354 ;BG18;Freund2017(28100831) ;BG18 contacts;Freund2017(28100831) ;IMGT/V-QUEST;IGHV4-4;;;21.0;NAIRIYGVVALGEWFHYGMDV;IGLV3-25;;11.0;QSSDTSDSYKM;L;354BG18; ;QVQLRESGPGLVKPSETLSLSCTVSNDSRPSDHSWTWVRQSPGKALEWIG;CAGGTTCAACTGCGGGAATCGGGCCCAGGACTGGTGAAGCCCTCGGAGACCCTGTCCCTCAGTTGCACTGTCTCTAATGACTCCCGCCCCAGTGACCACTCCTGGACTTGGGTCCGCCAGTCCCCAGGAAAGGCGCTGGAGTGGATTGGGGACATCCACTACAATGGGGCCACTACTTACAACCCGTCCCTCAGAAGTCGAGTCAGAATAGAACTGGACCAATCAATACCTCGCTTCTCCCTGAAGATGACCTCGATGACCGCCGCGGACACGGGCATGTATTACTGCGCGAGGAATGCCATTCGCATCTATGGTGTGGTTGCTTTGGGAGAGTGGTTCCACTACGGTATGGACGTCTGGGGCCAGGGGACCGCGGTCACCGTCTCGTCA;SSELTQPPSVSVSPGQTARITCSGAPLTSRFTYWYRQKPGQAPVLIISRS;TCCTCTGAACTGACACAGCCTCCCTCGGTGTCAGTTTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGGAGCTCCGTTGACAAGTCGCTTCACTTATTGGTACCGACAGAAGCCCGGCCAGGCCCCTGTTTTGATCATTTCGAGATCCAGTCAGAGGTCTTCAGGGTGGTCTGGGCGATTTTCTGCCTCCTGGTCAGGGACAACAGTCACATTGACCATAAGAGGCGTCCAGGCAGACGACGAGGCTGACTATTACTGTCAATCGTCAGACACCAGTGATTCTTATAAGATGTTTGGCGGAGGGACTAAGCTGACAGTCCTA;205.260905787786
BG8;gp120 V3 // V3 glycan (V3g);;EB354 ;BG18;Freund2017(28100831) ;;Freund2017(28100831) ;IMGT/V-QUEST;IGHV4-4;;;21.0;NVIRVFGFISLGEWFHYGMDV;IGLV3-25;;11.0;QSSDTSDSYKM;L;354BG8; ;;GAAGTTCAACTGCGAGAGTCGGGCCCACGACTGGTGAAGCCCTCCGAAACCCTGTCCCTCTCCTGCGATGTCTTTGGTGACTCCCGCCCCAGTGACCATTCCTGGACTTGGGTCCGCCAGCCCCCAGGGAAGGCCCTTGAGTGGATTGGAGACGTCCACTACAATGGAGATAATACATATAATCCGTCCCTCAGAGGTCGCGTCAAAATAGACGTGGACAGGTCCACACATCGGTTCTCCCTGACACTAAAGTCTTTGACCGCCGCGGACACGGGCATCTACTTCTGCGCGAGAAATGTCATTCGCGTCTTTGGTGTCATTTCCTTGGGAGAGTGGTTCCACTACGGTATGGACGTCTGGGGCCCGGGTACCGCGGTCATCGTCTCGTCA;;TCCTCTGAACTGACACAGGCACCCTCGGTGTCCGTGTCTCCAGGACAGACGGCCACGATCGCCTGCTCTGGACCTCCATTGGCGAGTCGATATACTTATTGGTACCGACAGAAGCCAGGCCAGGCCCCCGTCTTGATAATTTTTAGAGACAGGCAGTTTCCTTCAGGGGTCTCTGGGCGATTCTCTGCCTCCAAGTCCGGAACAACAGCTACCTTGACCATTCGAGACGTCCAAGTGGAAGACGAGGGTGACTATTATTGTCAATCATCAGACACCAGCGATTCTTATAAGATGTTTGGTGGAGGGACCACACTGACCGTCCTA;162.053430933438
CH01;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;;CH0219 ;CH01;Bonsignori2011(21795340) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,Mutation affects neutralization by V1V2 glycan mAbs,Mutation affects PG9-like Ab sensitivity,PG9-like antibodies require N160 for neutralization,PG9-like contacts,V2 Signature Analysis Summary;Bonsignori2011(21795340) ;SoDA;IGHV3-20;IGHD3-10;IGHJ2;24.0;;IGKV3-20;IGKJ1;9.0;;K;; ;EVQLVESGANVVRPGGSLRLSCKASGFIFENFGFSWVRQAPGKGLQWVAG;GAGGTTCAGCTGGTGGAGTCTGGGGCAAATGTTGTACGGCCGGGGGGGTCCCTGAGACTCTCCTGTAAAGCGTCCGGATTCATCTTTGAAAATTTTGGTTTTAGTTGGGTCCGCCAGGCTCCAGGGAAGGGGCTTCAGTGGGTCGCTGGTCTTAATTGGAATGGTGGTGACACACGTTATGCAGACTCTGTGAAGGGCCGATTCAGAATGTCCAGAGACAACTCCAGGAATTTTGTGTATTTGGACATGGATAAAGTGGGAGTCGACGACACGGCCTTCTATTACTGTGCGAGAGGGACCGATTACACTATTGACGACGCGGGGATCCATTACCAAGGTTCGGGGACCTTCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCAGTGTCTCTTCAG;EIVLAQSPGTLSLSPGERATLSCRASHNVHPKYFAWYQQKPGQSPRLLIY;GAAATTGTGTTGGCGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCACAATGTCCACCCCAAATATTTCGCCTGGTACCAGCAGAAGCCTGGCCAGTCTCCCCGACTCCTCATCTATGGTGGGTCCACCAGGGCCGCTGGCATTCCAGGCAAGTTCAGCGGCAGTGGGTCTGGGACCGACTTCACTCTCACCATCAGTCGAGTGGACCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATGGTGGCTCCCCGTACACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC;118.066198085093
CH103;gp120 CD4BS;4JAM(antibody CH103),4JAN(CH103 in complex with HIV-1 gp120);CH505 ;CH103;Liao2013(23552890) ;Antibody-driven selection in donor CH505,CH103 and CH235 evolution,CH103 contacts & bonding,hypervariable loop characteristic correlations with bNAb sensitivity,Signature Analysis Summary;Liao2013(23552890) ;IMGT/V-QUEST;IGHV4-59*01;IGHD3-16*01;IGHJ4*02;15.0;;IGLV3-1*01;IGLJ1*01;10.0;;L;; ;SETLSLTCTVSGGSMGGTYWSWLRLSPGKGLEWIGYIFHTGETNYSPSLK;TCGGAGACCCTGTCCCTCACTTGCACTGTCTCTGGTGGCTCCATGGGTGGGACTTATTGGAGTTGGCTGCGCCTGTCCCCCGGGAAGGGACTGGAATGGATTGGCTATATCTTTCATACTGGAGAGACCAATTACAGTCCCTCCCTGAAGGGTCGAGTCTCCATATCAGTGGACACGTCCGAGGACCAGTTCTCCCTGAGACTGAGGTCTGTGACCGCTGCGGACACGGCCGTCTATTTTTGTGCCAGTCTGCCCAGGGGCCAATTAGTCAATGCCTACTTTCGCAATTGGGGCCGCGGATCTCTGGTCTCCGTCACCGCA;YELTQPPSVSVSPGQTATITCSGASTNVCWYQVKPGQSPEVVIFENYKRP;CCTATGAGCTTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCACCATAACGTGCTCTGGGGCAAGTACAAATGTTTGCTGGTATCAGGTGAAGCCGGGCCAGTCCCCTGAGGTGGTCATCTTTGAGAATTATAAGCGGCCCTCAGGGATCCCTGACCGGTTCTCTGGCTCCAAGTCTGGGAGCACAGCCACTCTGACCATCCGCGGGACCCAGGCTATAGATGAGGCTGATTATTACTGTCAGGTGTGGGACAGCTTCTCCACCTTCGTCTTCGGATCTGGGACCCAGGTCACCGTCCTC;90.0896726254583
CH235;gp120 CD4BS;EMD-8083(B41 SOSIP.664 trimer in complex with CH235 Fab),EMD-8082(BG505 SOSIP.664 in complex with CH235 Fab),5F9W(CH235 in complex with HIV-1 clade AE 93TH057 gp120);CH505 ;CH235;Gao2014(25065977) ;Antibody-driven selection in donor CH505,CH103 and CH235 evolution;Bonsignori2016(26949186) ;Cloanalyst;IGHV1-46*01;IGHD3-10*01;IGHJ4*02;15.0;CARNVATEGSLLHYDYW;IGKV3-15*01;IGKJ1*01;8.0;QYNNWWTF;K;; ;QVQLVQSGAEVKKPGASVTVSCQASGYTFTNYYVHWVRQAPGQGLQLMGW;CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTTTCCTGCCAGGCATCTGGATACACCTTCACCAACTACTATGTACACTGGGTGCGACAGGCCCCTGGACAGGGGCTTCAATTGATGGGATGGATCGACCCTAGTTGGGGTCGCACAAACTACGCACAGAATTTCCAGGGCAGAATCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGATGAGAAGCCTGAGATCTGAGGACACGGCCGTTTATTATTGTGCGAGAAATGTGGCAACGGAGGGGAGCTTACTCCACTATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCGCA;EIVLTQSPATLSVSPGERATLSCRASQSVRSNLAWYQQRPGQAPRLLIYG;GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGAAGTAACTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCACCAGGGCCACTGGTGTCCCTGCCAGGTTCAGTGGCCGTGGGTCTGGGACAGAGTTCACTCTCGCCATCAGCAGCATGCAGTCTGAAGATTTTGCAGTTTATCTCTGTCTGCAGTATAATAACTGGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA;28.3638656701948
CH235.12;gp120 CD4BS;EMD-8079(B41 SOSIP.664 trimer in complex with CH235.12 Fab),EMD-8078(BG505 SOSIP.664 trimer in complex with CH235.12 Fab),5F96(CH235.12 in complex with HIV-1 clade AE 93TH057 gp120);CH505 ;CH235;Bonsignori2016(26949186) ;Antibody-driven selection in donor CH505,Electrostatic interactions with D368,hypervariable loop characteristic correlations with bNAb sensitivity,Signature Analysis Summary;Bonsignori2016(26949186) ;Cloanalyst;IGHV1-46*01;IGHD3-10*01;IGHJ4*02;15.0;CVRNVGTAGSLLHYDHW;IGKV3-15*01;IGKJ1*01;8.0;;K;CH557; ;QVQLAQYGGGVKRLGATMTLSCVASGYTFNDYYIHWVRQAPGQGFELLGY;CAGGTGCAACTAGCCCAATATGGTGGTGGGGTGAAGAGGCTAGGGGCCACAATGACCCTTTCCTGCGTGGCATCTGGATACACCTTCAACGACTACTACATACATTGGGTGCGGCAGGCCCCTGGACAAGGCTTTGAGTTGTTGGGATACATCGACCCCGCTAATGGTCGCCCAGACTACGCAGGGGCGTTGAGGGAGAGACTCTCCTTCTACAGGGACAAGTCCATGGAGACGCTGTACATGGACCTGAGGAGCCTAAGATATGACGACACGGCCATGTATTATTGTGTTAGAAATGTGGGGACCGCTGGCAGCTTGCTGCATTATGACCACTGGGGCTCGGGAAGCCCGGTCATCGTCTCCTCC;EIVLTQSPATLSASPGERVTLTCRASRSVRNNVAWYQHKGGQSPRLLIYD;GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCCGCGTCTCCAGGGGAAAGAGTCACCCTAACTTGCAGGGCCAGTCGGAGTGTCCGAAACAACGTGGCCTGGTATCAGCACAAGGGTGGCCAGAGTCCCAGGCTCCTCATTTATGATGCGTCCACGAGGGCCGCTGGTGTCCCAGCCAGGTTCAGCGGCAGTGCATCTGGGACAGAGTTCACTCTCGCCATCAGCAACTTGGAGTCTGAAGATTTTACAGTCTACTTCTGTCTGCAGTATAATAACTGGTGGACCTTCGGCCAAGGGACCAGGGTGGACATCAAA;187.069462619433
CH235.9;gp120 CD4BS;EMD-8080(B41 SOSIP.664 trimer in complex with CH235.9 Fab),EMD-8081(BG505 SOSIP.664 trimer in complex with CH235.9 Fab),5F9O(CH235.09 in complex with HIV-1 clade AE 93TH057 gp120);CH505 ;CH235;Bonsignori2016(26949186) ;Antibody-driven selection in donor CH505,Electrostatic interactions with D368;Bonsignori2016(26949186) ;Cloanalyst;IGHV1-46*01;IGHD3-10*01;IGHJ4*02;15.0;CVRNVGTAGSLLHYDHW;IGKV3-15*01;IGKJ1*01;8.0;;K;CH493; ;QVRLLQYGGGVKRPGASMTISCVASGYNFNDYYIHWVRQAPGQGLELMGW;CAGGTGCGACTACTACAATATGGGGGTGGAGTGAAGAGGCCTGGGGCCTCAATGACGATTTCCTGCGTGGCGTCTGGATACAACTTCAACGACTACTATATACACTGGGTGCGACAGGCCCCTGGACAAGGCCTCGAATTGATGGGATGGATCGACCCTAGTGGTGGTCGCACAGATTACGCAGGGGCGTTTGGGGACAGAGTGTCCATGTACAGGGACAAGTCCATGAACACACTCTACATGGACCTGAGGAGCCTGAGATCTGGCGACACGGCCATGTATTATTGTGTTAGAAATGTGGGAACGGCTGGCAGCTTGCTCCACTATGACCACTGGGGCCTGGGAGTTATGGTCACCGTCTCCTCA;;;114.359080821221
DH270.1;gp120 V3 // V3 glycan (V3g);5U0U(DH270.1 (unliganded, single-chain Fv));CH848 ;DH270;Bonsignori2017(28298420) ;V3 Signature Analysis Summary;Bonsignori2017(28298420) ;Cloanalyst;IGHV1-2*02;IGHD3-22*01;IGHJ4*02;20.0;TTGGWIGLYSDTSGYPNFDY;IGLV2-23*02;IGLJ2*01;10.0;CSYAGSSIIF;L;DH270; ;QVQLVQSGAEMKKPGASVRVSCKASGYTFTDYYIHWVRQAPGQGPEWMGW;CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGATGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGACTACTATATACACTGGGTGCGACAGGCCCCTGGACAAGGGCCTGAGTGGATGGGATGGATCAACCCTAGCACTGGTCGCACAAACTCTCCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGACCTGAACAGACTGACGTCTGACGACACGGCCATGTATTACTGTACGACCGGGGGGTGGATCGGTCTTTACTCTGATACTAGTGGTTACCCTAACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG;QSALTQPASVSGSPGQSITISCTGTNYDVGSYNLVSWYQQHPGKVPKYII;CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAATTATGATGTTGGGAGTTATAACCTTGTCTCCTGGTATCAACAGCACCCAGGCAAAGTCCCCAAATACATAATTTATGAGGTCAATAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCCACTTATTACTGTTGTTCATATGCAGGTAGTAGCATTATATTTTTCGGCGGTGGGACCAAGCTGACCGTCATAG;85.3292993993258
DH270.5;gp120 V3 // V3 glycan (V3g);5TPP(DH270.5 (unliganded));CH848 ;DH270;Bonsignori2017(28298420) ;V3 Signature Analysis Summary;Bonsignori2017(28298420) ;Cloanalyst;IGHV1-2*02;IGHD3-22*01;IGHJ4*02;20.0;VTGAWISDYYDSSYYPNFDH;IGLV2-23*02;IGLJ2*01;10.0;CSFGGSAAVV;L;DH471; ;QVQLVQSGAEVKNPGASVKVSCAPSGYTFTDFYIHWVRLAPGQGLEWLGW;CAGGTGCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAACCCTGGGGCCTCAGTGAAAGTCTCCTGCGCGCCTTCTGGATATACCTTCACTGACTTCTACATACACTGGGTGCGACTGGCCCCTGGACAAGGGCTTGAGTGGCTGGGGTGGATGAACCCTAAGACTGGTCGCACAAATCAAGGACAAAACTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCGGCACAGCCTACATGGAGTTGAGGAGCCTCACATCTGACGACACGGCCGTCTATTACTGTGTGACAGGGGCCTGGATCAGTGATTATTATGATAGTAGTTATTATCCTAACTTTGACCACTGGGGTCAGGGAACCCTGGTCACCGTCTCCTCAG;LPVLTQPASVSGSPGQSITISCTGTIYDVGKFDLVSWYQHHPGKAPKYLI;CTGCCTGTGCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGGCAGTCGATCACCATCTCCTGCACTGGGACCATTTATGATGTTGGGAAGTTTGACCTTGTCTCCTGGTACCAGCACCACCCAGGCAAAGCCCCCAAATATTTGATTTATGAAGTCAAAAAGTGGCCCTCAGGAGTTTCTCATCGCTTCTCTGGCTCCAAATCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGTTGAGGACGAGGCTGACTATTATTGCTGCTCATTCGGAGGTAGTGCCGCTGTGGTCTGCGGCGGAGGGACCAAGGTGACCGTCCTAG;110.556069873581
DH270.6;;5TQA(DH270.6 (unliganded));;DH270;;;Bonsignori2017(28298420) ;Cloanalyst;IGHV1-2*02;IGHD3-22*01;IGHJ4*02;20.0;TTGGWISGYYDSSYYPNFDH;IGLV2-23*02;IGLJ2*01;10.0;CSFGGSATVV;L;; ;QVQLVQSGAQMKNPGASVKVSCAPSGYTFTDFYIHWLRQAPGQGLQWMGW;CAGGTGCAGCTGGTGCAGTCTGGGGCTCAAATGAAGAACCCTGGGGCCTCAGTGAAGGTCTCCTGCGCGCCTTCTGGATATACCTTCACCGACTTTTACATACATTGGTTGCGCCAGGCCCCTGGCCAGGGGCTTCAGTGGATGGGATGGATGAACCCTCAGACTGGTCGCACAAACACTGCACGAAACTTTCAGGGGAGGGTCACCATGACCAGGGACACGTCCATCGGCACAGCCTACATGGAGTTGAGAAGCCTGACATCTGACGACACGGCCATATATTACTGTACGACAGGGGGATGGATCAGTCTTTACTATGATAGTAGTTATTACCCCAACTTTGACCACTGGGGTCAGGGAACCCTGCTCACCGTCTCCTCAG;QSALTQPASVSGSPGQSITISCTGTKYDVGSHDLVSWYQQYPGKVPKYMI;CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAAGTATGATGTTGGGAGTCATGACCTTGTCTCCTGGTACCAACAGTACCCAGGCAAAGTCCCCAAATACATGATTTATGAAGTCAATAAACGGCCCTCAGGAGTTTCTAATCGCTTCTCTGGCTCCAAATCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCGGGCTGAGGACGAGGCTGACTATTATTGCTGTTCATTTGGAGGGAGTGCCACCGTGGTCTGCGGCGGCGGGACCAAGGTGACCGTCCTA;140.967376078295
DH511.11P;gp41 MPER (membrane proximal external region);5U3M(DH511.11P Fab in Complex with HIV-1 gp41 MPER Peptide);CH0210 ;DH511;Williams2017(28783671) ;;Williams2017(28783671) ;IMGT/V-QUEST;IGHV3-15*01;IGHD3-3*01;IGHJ6*03;23.0;TADEGAPILRFFEWGYYNYYMDV;IGKV1-39*01;IGKJ2*01;11.0;QESYSSVPMYI;K;; ;QVQLVQSGGGLVKPGGSLTLSCVTSGFTFSNTWMSWVRQTPGKGLEWVAR;CAGGTCCAGCTGGTACAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTACACTCTCCTGTGTCACCTCTGGATTTACTTTCAGCAACACGTGGATGAGTTGGGTCCGCCAGACTCCAGGGAAGGGACTGGAGTGGGTTGCCCGTATTAGTAGGGTCGGGGATGGCCCAATAATAGACTACGCTGCTCCCGTGAAAGGCAGATTCATAATCTCAAGAGATGACTCAAGAAACACACTCTTTCTTCACATGAACAACCTGAAAACCGAGGACACAGCCGTGTATTATTGTACCGCTGATGAGGGGGCCCCAATTTTAAGATTTTTTGAGTGGGGTTATTACAACTACTACATGGACGTCTGGGGCAAGGGGACCACGGTCATCGTCTCCTCG;DIRLTQSPSSLSASVGDRITITCRASQSIKDYLNWYKHRPGEAPKLLIYS;GACATCCGGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGGGACAGAATCACCATCACTTGTCGGGCCAGCCAAAGCATTAAAGACTATTTAAATTGGTATAAACACCGGCCAGGGGAAGCCCCCAAACTCCTCATTTATTCTGCATCCAAGTTGAGAAGTGGGGTCTCATCAAGGTTCAGTGGCAGTGGATATGGGTCGGCCTTCACACTGACCATCAGCAGTCTGCAGCCTGAAGATTTTGCGACTTATTATTGTCAGGAGAGTTACAGCAGCGTTCCCATGTACATTTTCGGCCAGGGGACCAAGGTGGACCTCAAAC;205.220790724921
DH511.12P;gp41 MPER (membrane proximal external region);5U3N(DH511.12P Fab in Complex with HIV-1 gp41 MPER Peptide);CH0210 ;DH511;Williams2017(28783671) ;;Williams2017(28783671) ;IMGT/V-QUEST;IGHV3-15*01;IGHD3-3*01;IGHJ6*03;23.0;TADEGAPILRFFEWGYYNYYMDV;IGKV1-39*01;IGKJ2*01;11.0;QESYSSVPMYI;K;; ;QVQLVQSGGGLVKPGGSLTPSCVTSGFTFSNTWMSWVRQTPGKGLEWVAR;CAGGTCCAGCTTGTACAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTACACCCTCCTGTGTCACCTCTGGATTTACTTTCAGCAACACGTGGATGAGTTGGGTCCGCCAGACTCCAGGGAAGGGACTGGAGTGGGTTGCCCGTATTAGTAGGGTCGGGGATGGCCCAATAATAGACTACGCTGCTCCCGTGAAAGGCAGATTCATAATCTCAAGAGATGACTCAAGAAACACACTCTTTCTTCACATGAACAACCTGAAAACCGAGGACACAGCCGTGTATTATTGTACCGCTGATGAGGGGGCCCCAATTTTAAGATTTTTTGAGTGGGGTTATTACAACTACTACATGGACGTCTGGGGCAAGGGGACCACGGTCATCGTCTCCTCG;DIRLTQSPSSLSASVGDRITITCRASQSIKDYLNWYKHRPGEAPKLLIYS;GACATCCGGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGGGACAGAATCACCATCACTTGTCGGGCCAGCCAAAGCATTAAAGACTATTTAAATTGGTATAAACACCGGCCAGGGGAAGCCCCCAAACTCCTCATTTATTCTGCATCCAAGTTGAGAAGTGGGGTCTCATCAAGGTTCAGTGGCAGTGGATATGGGTCGGCCTTCACACTGACCATCAGCAGTCTGCAGCCTGAAGATTTTGCGACTTATTATTGTCAGGAGAGTTACAGCAGCGTTCCCATGTACATTTTCGGCCAGGGGACCAAGGTGGACCTCAAAC;209.890971217169
DH511.2;gp41 MPER (membrane proximal external region);5U3K(DH511.2 Fab in Complex with HIV-1 gp41 MPER 662-683 Peptide),5U3L(DH511.2 Fab in Complex with HIV-1 gp41 MPER 670-683 Peptide);CH0210 ;DH511;Williams2017(28783671) ;DH511.2 and DH511.2_K3 contacts,Signature Analysis Summary;Williams2017(28783671) ;IMGT/V-QUEST;IGHV3-15*01;IGHD4-4*01;IGHJ6*03;23.0;TMDEGTPVTRFLEWGYFYYYMAV;IGKV1-39*01;IGKJ2*03;11.0;QENYNTIPSLS;K;; ;QVQLVQSGGGLVKPGGSLTLSCSASGFFFDNSWMGWVRQAPGKGLEWVGR;CAGGTGCAGCTGGTACAGTCTGGGGGAGGTCTGGTGAAGCCGGGGGGGTCCCTCACACTCTCCTGTTCAGCCTCTGGATTCTTTTTCGATAATTCATGGATGGGGTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTTGGCCGCATTAGAAGGCTCAAAGACGGTGCGACAGGAGAATATGGTGCAGCCGTGAAGGACAGATTCACCATTTCAAGAGATGACAGTAGAAATATGCTGTACCTGCACATGAGGACCCTGAAAACCGAGGACTCAGGCACTTATTATTGTACCATGGATGAGGGGACCCCAGTAACACGCTTCTTAGAATGGGGCTACTTCTATTATTATATGGCCGTTTGGGGCAGAGGGACCACGGTCATCGTCTCTTCA;DIVMTQSPSSVSASVGDRVTITCRASQNIRDYLNWYQHKPGGSPRLLIYA;GACATCGTGATGACCCAGTCTCCGTCCTCCGTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAATATTAGAGACTATTTAAATTGGTATCAACATAAACCCGGGGGATCCCCTAGACTCCTAATTTATGCTGCGTCAACTTTGCAAACTGGGGTCCCGTCCAGATTCAGCGGCAGTGGATCTGGGAACCTTTTCACTCTCACCATTACCAATCTGCAACCTGAAGATTTTGCAACTTATTATTGTCAAGAGAATTATAATACTATCCCCTCGCTCAGCTTTGGTCAGGGGACCAAGGTGGACATCAGGC;194.986192016875
F105;gp120 CD4BS;1U6A(Fab F105),3HI1(gp120 (core with V3) complex with F105);;;Posner1991(1710248) ;Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs;;;;;;;;;;;;K;F-105; ;MKHLWFFLLLVAAPRWVLSQVQLQESGPGLVKPSETLSLTCTVSGGSISS;ATGAAACATCTGTGGTTCTTCCTTCTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGAGGCTCCATCAGTAGTCACTACTGGAGCTGGATCCGGCAGTCCCCAGGGAAGGGACTGCAGTGGATTGGATATATCTACTACAGTGGGAGCACCAACTACAGCCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGAGACGTCCAAGAACCAGTTCTCCCTGAAGCTGACCTCTATGACCGCTGCGGACACGGCCGTGTATTACTGTGCGCGA;METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSAGERATLSCRASQSVS;ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTGCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGGTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGAGTGGAGCCTGAAGATTTTGCAGGTTATTACTGTCAGCAATATGATAACTCCGTTTGCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGA;4.45618597921273
HJ16;gp120 CD4BS;4YE4(Neutralizing Antibody HJ16 in Complex with HIV-1 gp120);VI3208 ;;Corti2010(20098712) ;HJ16 binding requires N276,HJ16 contacts,Mutation decreases binding to CD4BS mAbs,Signature Analysis Summary;Wu2011(21835983) ;IgBlast;IGHV3-30*18;;;;;IGKV4-1*01;;;;K;HJ16_22; ;QMKLMQSGGVMVRPGESATLSCVASGFDFSRNGFEWLRQGPGKGLQWLAT;CAGATGAAGTTGATGCAGTCGGGGGGAGTCATGGTCCGGCCTGGAGAATCGGCGACACTGTCTTGTGTTGCCTCTGGATTCGACTTCAGTCGCAATGGGTTCGAGTGGCTCCGCCAGGGTCCCGGCAAGGGGCTGCAGTGGCTGGCCACAGTCACCTTCGAAAGTAAGACACATGTCACGGCCTCCGCGCGGGGCCGATTCACTATTTCTAGAGACAATTCCAGGAGAACCGTCTATTTGCAAATGACTAATCTGCAGCCTGACGATACGGCAATGTATTTCTGTGTTAAAGACCAGACTATTTTTCACAAAAATGGAGCCGTCGATTTCTTCTCGTACTTCGACCTGTGGGGCCGTGGCGCCCCGGTCATAGTCTCCGCAG;DVVMTQSPEFLAVSLGERATLECKSSHSLLYAPYDKDALVWYQQKPGQPP;GACGTCGTGATGACCCAGTCTCCAGAATTCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCCTCGAATGCAAGTCCAGCCACAGTCTTTTATATGCCCCCTACGATAAGGATGCCTTAGTTTGGTATCAGCAAAAACCAGGGCAGCCTCCAAAGTTGCTCCTTGACTGGGCATCAAGTCGTCGCTCCGGGGTCTCTGACCGATTCAGTGCCACCAGCGCATCTGGGAGATACTTTACTCTTACGATTAGCAATTTCCGGGCTGACGACGTGGCGACTTATTATTGTCAACAGACCCGCTGGACTCCCCCTACCTTCGGCGGCGGGACCAAGGTGGATCTCAACC;67.6365009276559
IOMA;gp120 CD4BS;6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA),5T3X(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074),5T3Z(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);R1 ;;Gristick2016(27617431) ;IOMA contacts;Gristick2016(27617431) ;IgBlast;IGHV1-2*02;;;16.0;EMFDSSADWSPWRGMVA;IGLV2-23*02;;8.0;YSYADGVAF;L;IOMA.25; ;EVQLVESGAQVKKPGASVTVSCTASGYKFTGYHMHWVRQAPGRGLEWMGW;GAGGTGCAGCTGGTGGAGTCTGGGGCTCAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTCTCCTGCACGGCATCTGGATACAAGTTCACCGGCTACCATATGCACTGGGTGCGACAGGCCCCTGGACGCGGGCTTGAGTGGATGGGATGGATCAACCCTTTCAGGGGTGCCGTAAAGTATCCACAGAATTTTCGGGGCAGGGTCTCCATGACCAGGGACACGTCCATGGAAATATTTTACATGGAGTTGAGCAGACTGACATCTGACGACACGGCCGTCTATTATTGTGCGAGAGAAATGTTCGATAGCAGTGCTGATTGGTCTCCCTGGCGCGGTATGGTGGCCTGGGGCCAGGGGACCCTGGTCACCGTCTCCTCAG;QSALTQPASVSGSPGQSITISCAGSSRDVGGFDLVSWYQQHPGKAPKLII;CAGTCTGCGCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCGCTGGGTCCAGCCGTGATGTTGGGGGTTTTGACCTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATAATTTATGAGGTCAATAAGCGGCCCTCAGGGATTTCTAGTCGCTTCTCTGCCTCCAAGTCCGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGAAGAGGACGAGGCTCATTATTATTGTTACTCATATGCAGATGGTGTAGCCTTTGGCGGAGGGACCAAGCTGACCGTCCTAG;69.1094254913355
N6;gp120 CD4BS;5TE5(N6 in Complex with HIV-1 Clade AE Strain 93TH057 gp120 Core),5TE6(N6 in Complex with HIV-1 Clade C Strain DU172.17 gp120 Core),5TE4(N6 in Complex with HIV-1 Clade G Strain X2088 gp120 Core);Z258 ;;Huang2016a(27851912) ;hypervariable loop characteristic correlations with bNAb sensitivity,Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs,N6 alanine scanning,N6 contacts,Signature Analysis Summary;Huang2016a(27851912) ;IMGT/V-QUEST;IGHV1-2*02;IGHD2-21*02;IGHJ6*01;13.0;CARDRSYGDSSWALDAWGQGTTVVVSA;IGKV1-33*01,IGKV1D-33*01;IGKJ5*01;5.0;QVLQF;K;N6-LS; ;RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVGW;CGAGCGCACCTGGTACAATCAGGGACTGCGATGAAGAAACCGGGGGCCTCAGTAAGAGTCTCCTGCCAGACCTCTGGATACACCTTTACCGCCCACATATTATTTTGGTTCCGACAGGCCCCCGGGCGAGGACTTGAGTGGGTGGGGTGGATCAAGCCACAATATGGGGCCGTGAATTTTGGTGGTGGTTTTCGGGACAGGGTCACATTGACTCGAGACGTATATAGAGAGATTGCGTACATGGACATCAGAGGCCTTAAACCTGACGACACGGCCGTCTATTACTGTGCGAGAGACCGTTCCTATGGCGACTCCTCTTGGGCCTTAGATGCCTGGGGACAGGGAACGACGGTCGTCGTCTCCGCG;YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIHH;TACATCCACGTGACCCAGTCTCCGTCCTCCCTGTCTGTGTCTATTGGAGACAGAGTCACCATCAATTGCCAGACGAGTCAGGGTGTTGGCAGTGACCTACATTGGTATCAACACAAACCGGGGAGAGCCCCTAAACTCTTGATCCACCATACCTCTTCTGTGGAAGACGGTGTCCCCTCAAGATTCAGCGGCTCTGGATTTCACACATCTTTTAATCTGACCATCAGCGACCTACAGGCTGACGACATTGCCACATATTACTGTCAAGTTTTACAATTTTTCGGCCGAGGGAGTCGACTCCATATTAAA;315.33531738548
NIH45-46;gp120 CD4BS;4JDT(chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 (93TH057)),3U7W(Fab NIH45-46),3U7Y(Fab NIH45-46 complexed with gp120),4JDV(germ-line precursor of NIH45-46 Fab),5IGX(NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120);NIH45 ;VRC01 ;Scheid2011(21764753) ;hypervariable loop characteristic correlations with bNAb sensitivity,NIH45-46 contacts,NIH45-46 signature predictions (West2013),Signature Analysis Summary,Signature Analysis Summary;Zhou2013a(23911655) ;IgBlast IMGT/V-QUEST;IGHV1-02*02;;;16.0;GKYCTARDYYNWDFEH;IGKV3-20*01;IGKJ2*01;5.0;QQYEF;K;45, 45-46; ;QVRLSQSGGQMKKPGESMRLSCRASGYEFLNCPINWIRLAPGRRPEWMGW;CAAGTGCGACTGTCGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGACTTTCCTGTCGGGCTTCCGGATATGAATTTCTGAATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAGTGGATGGGATGGCTGAAGCCTAGGGGAGGGGCCGTCAATTACGCACGTAAATTTCAGGGCAGAGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATATTGTACTGCGCGCGACTATTATAATTGGGACTTCGAACACTGGGGCCGGGGTGCCCCGGTCACCGTCTCATCAGCGTCGACCAAGGGCCCATCGGT;EIVLTQSPATLSLSPGETAIISCRTSQSGSLAWYQQRPGQAPRLVIYSGS;GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTCTGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGTTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCAGCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATCAAACGTACGGTGGCTGCACCA;237.501757279878
PCDN-33A;gp120 V3 // V3 glycan (V3g);;PC76 ;;MacLeod2016(27192579) ;Sites affecting neutralization of PCDN lineage mAbs;;;;;;;;;;;;K;33A; ;QVQLQQWGAGLVKPSEPLSLTCAVYGGSFTDYQWSWIRQSPGKGLEWIGE;CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGGTGAAGCCCTCGGAGCCCCTGTCCCTCACCTGCGCTGTCTATGGTGGGTCCTTCACTGACTACCAGTGGAGTTGGATCCGCCAGTCCCCCGGGAAGGGGCTGGAGTGGATTGGCGAAATCGATTATCTTGAAAACGTCAACTACAACCCGTCACTCAGGGGACGATTCACCATATCTGTGGACACGTCCAAGAACCAATTCTCCTTGAAATTTTTCTCCGCGACCGCCGCGGACACGGCTGTCTATTACTGTGCGAGAGGAGGCCGGAAAATTTGTTACGATTATTGGTGTGGCTATGTTAACAACTGCTTCGACACCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA;EIVLTQSPGTLALSPGESASLSCRANQTVTDNCLAWYQRKGGQAPRLLLY;GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGGCTTTGTCTCCAGGGGAAAGCGCCTCCCTCTCCTGCAGGGCCAATCAAACCGTCACCGACAACTGTTTAGCCTGGTACCAGCGAAAAGGTGGCCAGGCTCCCAGACTCCTCCTATATGGGGTATCCAACAGGGCCACTGGCATTCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCAACATCAGCAGACTGGGGCCTGAAGACGTTGGAGTGTATTACTGTCAGCAGTGTGGTAGCTCACCGACGTTCGGCCAGGGGACCAAGGTGGAGATCAAAC;112.791447970926
PCDN-38A;gp120 V3 // V3 glycan (V3g);;PC76 ;;MacLeod2016(27192579) ;Sites affecting neutralization of PCDN lineage mAbs;Longo2016(27654288) ;IMGT/V-QUEST JoinSolver;IGHV4-34*01;;IGHJ5*01;22.0;ARGGRKICYDYWCGYVNNCFDT;IGKV3-20*01;IGKJ1*01;8.0;QQCGSSPT;K;38A, PCDN38A; ;QVQLQQWGTGLLKPSESLFLTCAVYNEDLSAFSWSWIRQSPGKGLEWIGE;CAGGTGCAGCTACAGCAGTGGGGCACAGGGCTGTTGAAGCCTTCGGAGTCCCTGTTCCTCACCTGCGCTGTCTATAATGAGGACTTGAGTGCTTTCTCCTGGAGTTGGATCCGCCAGTCCCCCGGTAAGGGGCTGGAGTGGATTGGCGAAATCGATCATCTTCAAAACGTCAATTACAATCCGTCCCTCAAGGGTCGGTTCACCATATCAATTGACACGTCCAAGAATCAGTTCTCCCTGAGGTTCTTCTCTGTGACCGCCGCGGACGCGGCTATGTATTACTGTGCGAGGGGAGGCCGCAAAGTTTATCACCCTTATTGGACTGGCTATGTGAACAATTGCTTTGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA;EIVLTQSPGALSLSPGERASLSCRASQSVSDKNLAWYQQRPGLPPRLLIY;GAAATTGTGTTGACGCAGTCTCCAGGCGCCCTGTCTTTGTCTCCGGGGGAGAGAGCCAGCCTCTCCTGCAGGGCCAGCCAGAGTGTCAGCGACAAGAACTTAGCCTGGTACCAGCAGAGACCTGGCCTGCCTCCCAGACTCCTCATATATGGTGTCTCCTTAAAAAACACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAAACTTCACTCTCACCATCAGCAGCCTGGAGTCTGAAGATTCCGCAGTGTATTTCTGTCAGCAGTATGGTAGCTCACCGACCTTCGGCCAAGGGACCAAGGTGGAGATCAAAC;80.161934043578
PCDN-38B;gp120 V3 // V3 glycan (V3g);;PC76 ;;MacLeod2016(27192579) ;Sites affecting neutralization of PCDN lineage mAbs;;;;;;;;;;;;K;38B; ;QVQLQQWGTGLLKPSESLFLTCAVYNESMSAFSWSWIRQSADKGLEWIGE;CAGGTGCAGCTACAGCAGTGGGGCACAGGGCTGTTGAAGCCTTCGGAGTCCCTGTTCCTCACCTGCGCTGTCTATAATGAGTCCATGAGCGCTTTCTCTTGGAGTTGGATCCGCCAATCTGCCGATAAGGGGCTGGAATGGATTGGCGAAATCGATCATCTTCAACACGTCAACTACAATCCGTCCCTCACGGGTCGATTCACCATATCAATTGACACGTCCAAGAATCAGTTCTCCCTGAGGTTCTTCTCTGTGATTGCCGCGGACGCGGCTATGTATTACTGTGCGAGGGGAGGCCGCAAAGTCTATCACGCTTATTGGACTGGCTATGTGAATAATTGTTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA;EIVLTQSPGTLSLSPGETASLSCRASQSVSDKNLAWYQQRPGLPPRLLIY;GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTATCTCCAGGGGAGACAGCCAGCCTCTCCTGCAGGGCCAGCCAGAGTGTCAGCGACAAGAACTTAGCCTGGTACCAGCAGAGACCTGGCCTGCCTCCCAGACTCCTCATATATGGTGTCTCCTTAAAAAACACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAAACTTCACTCTCACCATCACCAGCCTGGAGTCTGAAGATTCCGCAGTGTATTTCTGTCAGCAGTATGGGAGCTCACCGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAAC;101.143951743802
PG16;gp120 V2 // V2 glycan(V2g) // V2 apex;4DQO(Fab PG16 complexed with V1V2 region (ZM109)),3MUG(PG16 Fab),3MME(Structure and functional dissection of PG16),3LRS(Structure of PG16);24 ;PG9;Walker2009a(19729618) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,hypervariable loop characteristic correlations with bNAb sensitivity,Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs,Mutation affects neutralization,Mutation affects PG9-like Ab sensitivity,PG16 signature predictions (West2013),PG9-like antibodies require N160 for neutralization,PG9-like contacts,V2 Signature Analysis Summary;Pancera2010(20538861) ;IMGT/V-QUEST JoinSolver;IGHV3-33*05;IGHD3-3*01;IGHJ6*03;;;IGLV2-14*01;IGLJ3*02;;;L;; ;QEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVAL;CAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGATTCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACACGGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCGAGC;QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMV;CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAATGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCCTGGTACCAACAATCCCCAGGGAAAGCCCCCAAAGTCATGGTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTCTTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTA;262.311124946514
PG9;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;3U36(Fab PG9  ),3U4E(Fab PG9 complexed with V1V2 region (CAP45)),3U2S(Fab PG9 complexed with V1V2 region (ZM109)),3MUH(PG9 light chain);24 ;PG9;Walker2009a(19729618) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,hypervariable loop characteristic correlations with bNAb sensitivity,Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs,Mutation affects neutralization,Mutation affects neutralization by V1V2 glycan mAbs,Mutation affects PG9-like Ab sensitivity,PG9 escape mutations,PG9-like antibodies require N160 for neutralization,PG9-like contacts,PG9 residue prediction,PG9 signature predictions (West2013),V2 Signature Analysis Summary;Pancera2010(20538861) ;IMGT/V-QUEST JoinSolver;IGHV3-33*05;IGHD3-3*01;IGHJ6*03;;;IGLV2-14*01;IGLJ3*02;;;L;; ;QRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFI;CAGCGATTAGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGTCGTCCCTGAGACTCTCCTGTGCAGCGTCCGGATTCGACTTCAGTAGACAAGGCATGCACTGGGTCCGCCAGGCTCCAGGCCAGGGGCTGGAGTGGGTGGCATTTATTAAATATGATGGAAGTGAGAAATATCATGCTGACTCCGTATGGGGCCGACTCAGCATCTCCAGAGACAATTCCAAGGATACGCTTTATCTCCAAATGAATAGCCTGAGAGTCGAGGACACGGCTACATATTTTTGTGTGAGAGAGGCTGGTGGGCCCGACTACCGTAATGGGTACAACTATTACGATTTCTATGATGGTTATTATAACTACCACTATATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCGAGC;QSALTQPASVSGSPGQSITISCNGTSNDVGGYESVSWYQQHPGKAPKVVI;CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCAATGGAACCAGCAATGATGTTGGTGGCTATGAATCTGTCTCCTGGTACCAACAACATCCCGGCAAAGCCCCCAAAGTCGTGATTTATGATGTCAGTAAACGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGGTGACTATTACTGCAAGTCTCTGACAAGCACGAGACGTCGGGTTTTCGGCACTGGGACCAAGCTGACCGTTCTA;258.493696600606
PGDM1400;gp120 V2 // V2 glycan(V2g) // V2 apex;4RQQ(Fab PGDM1400);84 ;;Sok2014(25422458) ;hypervariable loop characteristic correlations with bNAb sensitivity,PGDM1400 lineage requires N160,V2 Signature Analysis Summary;Sok2014(25422458) ;IMGT/V-QUEST;IGHV1-8;;IGHJ6;34.0;CAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFW;IGKV2-28;IGKJ1;9.0;CMQGRESPWTF;K;; ;QAQLVQSGPEMRKPGASVKVSCKAPGNTLKNHDLHWVRNVPGQGLEWVGW;CAGGTGCATCTGACGCAGTCTGGGCCTGAGGTGAGGAAGCCTGGGACCTCCGTAAAGGTCTCCTGCAAGGCCCCTGGAAACACATTGAAGACTTATGATCTACACTGGGTGCGCAGCGTCCCTGGACAAGGCCTTCAGTGGATGGGATGGATAAGCCATGAGGGCGACAAGAAGGTCATTGTGGAAAGATTCAAGGCCAAAGTCACCATTGATTGGGACAGGTCCACCAATACGGCCTATCTCCAACTGAGCGGCCTCACATCTGGCGACACGGCCGTCTATTATTGTGCGAAAGGCTCAAAACACAGGCTGCGAGATTACGCTCTCTACGACGACGACGGCGCATTGAATTGGGCTGTCGATGTTGACTACCTTTCGAACTTGGAATTCTGGGGCCAAGGGACCGCCGTCACCGTCTCTTCA;DFVLTQSPHSLSVTPGESASISCKSSHSLIHGDRNNYLAWYVQKPGRSPQ;GATTTTGTCCTGACTCAGTCTCCACACTCTCTGTCCGTCACCCCTGGAGAGTCGGCCTCCATCTCCTGCAAGTCTAGTCACAGCCTCATTCATGGTGATAGGAACAATTATTTGGCTTGGTACGTACAGAAGCCAGGGCGGTCTCCACAACTCCTGATCTATTTGGCTTCCAGTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCGGACAAAGATTTTACACTGAAGATCAGCAGAGTGGAGACTGAGGATGTTGGGACGTATTACTGCATGCAAGGTCGAGAAAGTCCCTGGACGTTCGGCCAAGGGACCAAGGTGGACATCAAA;294.920676893916
PGT121;gp120 V3 // V3 glycan (V3g);4JY4(Fab PGT121),4FQQ(germline antibody PGT121-GL Fab),4FQ1(PGT121 Fab),4FQC(PGT121 Fab bound to a complex-type sialylated N-glycan);17 ;PGT121;Walker2011(21849977) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,hypervariable loop characteristic correlations with bNAb sensitivity,Key sites for PGT121-like and 10-1074-like mAbs,Mutation affects neutralization of V3 mAbs,Mutation greatly reduces PGT121 neutralization,PGT121-123, 125-128, 130, 131 sites important for neutralization,PGT121 family and N137 glycan,PGT121 signature predictions (West2013),V3 Signature Summary;Sok2013(24278016) ;IMGT/V-QUEST;IGHV4-59;;IGHJ6*03;26.0;CARTLHGRRIYGIVAFNEWFTYFYMDVW;IGLV3-21;IGLJ3*02;15.0;DYYCHIWDSRVPTKWVF;L;PGT-121; CDR3 sequences are longer in Sok2013 than reported in Walker2011.;QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGY;CAGATGCAGTTACAGGAGTCGGGCCCCGGACTGGTGAAGCCTTCGGAAACCCTGTCCCTCACGTGCAGTGTGTCTGGTGCCTCCATAAGTGACAGTTACTGGAGCTGGATCCGGCGGTCCCCAGGGAAGGGACTTGAGTGGATTGGGTATGTCCACAAAAGCGGCGACACAAATTACAGCCCCTCCCTCAAGAGTCGAGTCAACTTGTCGTTAGACACGTCCAAAAATCAGGTGTCCCTGAGCCTTGTGGCCGCGACCGCTGCGGACTCGGGCAAATATTATTGCGCGAGAACACTGCACGGGAGGAGAATTTATGGAATCGTTGCCTTCAATGAGTGGTTCACCTACTTCTACATGGACGTCTGGGGCAATGGGACTCAGGTCACCGTCTCCTCA;SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGI;TCCGATATATCTGTGGCCCCAGGAGAGACGGCCAGGATTTCCTGTGGGGAAAAGAGCCTTGGAAGTAGAGCTGTACAATGGTATCAACACAGGGCCGGCCAGGCCCCCTCTTTAATCATATATAATAATCAGGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCCCTGACTCCCCTTTTGGGACCACGGCCACCCTGACCATCACCAGTGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCATATATGGGATAGTAGAGTTCCCACCAAATGGGTCTTCGGCGGAGGGACCACGCTGACCGTGTTA;187.476373879909
PGT123;gp120 V3 // V3 glycan (V3g);4JY6(Fab PGT123);17 ;PGT121;Walker2011(21849977) ;Mutation greatly reduces PGT123 neutralization,PGT121-123, 125-128, 130, 131 sites important for neutralization,PGT121 family and N137 glycan,V3 Signature Analysis Summary;Sok2013(24278016) ;IMGT/V-QUEST;IGHV4-59;;IGHJ6*03;26.0;CARALHGKRIYGIVALGELFTYFYMDVW;IGLV3-21;IGLJ3*02;15.0;DYYCHIYDARGGTNWVF;L;PGT-123; CDR3 sequences are longer in Sok2013 than reported in Walker2011.;QLHLQESGPGLVKPPETLSLTCSVSGASINDAYWSWIRQSPGKRPEWVGY;CAGCTGCACCTGCAGGAGTCGGGCCCAGGGCTGGTGAAGCCTCCGGAGACCCTGTCCCTCACGTGTAGTGTGTCTGGCGCCTCCATCAATGATGCCTATTGGAGTTGGATTCGGCAGTCCCCAGGGAAGCGGCCTGAGTGGGTTGGATATGTCCATCACAGCGGTGACACAAATTATAATCCCTCACTCAAGAGGCGCGTCACGTTTTCATTAGACACGGCCAAGAATGAAGTGTCCCTGAAATTAGTAGACCTGACCGCTGCGGACTCGGCCACATATTTTTGTGCGCGAGCACTTCACGGGAAGAGGATTTATGGGATAGTTGCCCTCGGAGAGTTGTTCACCTACTTCTACATGGACGTCTGGGGCAAGGGGACTGCGGTCACCGTCTCCTCA;SSMSVSPGETAKISCGKESIGSRAVQWYQQKPGQPPSLIIYNNQDRPAGV;TCCTCTATGTCCGTGTCCCCGGGGGAGACGGCCAAGATCTCCTGTGGAAAAGAGAGCATTGGTAGCAGAGCTGTGCAATGGTATCAGCAGAAGCCAGGCCAGCCCCCCTCATTGATTATCTATAATAATCAGGACCGCCCCGCAGGGGTCCCTGAGCGATTCTCTGCCTCCCCTGACTTCCGTCCTGGGACCACGGCCACCCTGACCATCACCAATGTCGACGCCGAGGATGAGGCCGACTATTACTGTCATATATATGATGCTAGAGGTGGCACCAATTGGGTCTTCGACAGAGGGACCACACTGACCGTCTTA;173.349661228083
PGT125;gp120 V3 // V3 glycan (V3g);;36 ;PGT128;Walker2011(21849977) ;Mutation greatly reduces PGT125 neutralization,PGT121-123, 125-128, 130, 131 sites important for neutralization,V3 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV4-39*07;;IGHJ5*02;19.0;FDGEVLVYNHWPKPAWVDL;IGLV2-8*01;IGLJ2*01,IGLJ3*01;10.0;GSLVGNWDV;L;PGT-125; ;QSQLQESGPRLVEASETLSLTCNVSGESTGACTYFWGWVRQAPGKGLEWI;CAGTCGCAGCTGCAGGAGTCGGGCCCACGACTGGTGGAGGCCTCGGAGACCCTGTCACTCACGTGCAATGTGTCCGGCGAGTCCACTGGTGCCTGTACTTATTTCTGGGGCTGGGTCCGGCAGGCCCCAGGGAAGGGGCTGGAGTGGATCGGGAGTTTGTCCCATTGTCAGAGTTTCTGGGGTTCCGGTTGGACCTTCCACAACCCGTCTCTCAAGAGTCGACTCACGATTTCACTCGACACGCCCAAGAATCAGGTCTTCCTCAAGCTCACTTCTCTGACTGCCGCGGACACGGCCACTTACTACTGTGCGCGATTCGACGGCGAAGTCTTGGTCTATAATCATTGGCCAAAGCCGGCCTGGGTGGACCTCTGGGGCCGCGGAATACCGGTCACCGTCACCGTCTCCTCA;QSALTQPPSASGSPGQSITISCNGTATNFVSWYQQFPDKAPKLIIFGVDK;CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCACCATCTCCTGCAATGGAACCGCCACTAACTTTGTCTCCTGGTACCAACAATTCCCAGACAAGGCCCCCAAACTCATCATTTTTGGGGTCGATAAGCGCCCCCCCGGTGTCCCCGATCGTTTCTCTGGCTCCCGGTCTGGCACGACGGCCTCCCTTACCGTCTCCCGACTCCAGACTGACGATGAGGCTGTCTATTATTGCGGTTCACTTGTCGGCAACTGGGATGTGATTTTCGGCGGAGGGACCACCTTGACCGTCCTA;115.971445763275
PGT126;gp120 V3 // V3 glycan (V3g);;36 ;PGT128;Walker2011(21849977) ;Mutation greatly reduces PGT126 and PGT127 neutralization,PGT121-123, 125-128, 130, 131 sites important for neutralization,V3 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV4-39*07;;IGHJ5*02;19.0;FDGEVLVYHDWPKPAWVDL;IGLV2-8*01;IGLJ2*01,IGLJ3*01;10.0;SSLVGNWDVI;L;PGT-126; ;QPQLQESGPGLVEASETLSLTCTVSGDSTAACDYFWGWVRQPPGKGLEWI;CAGCCGCAGCTGCAGGAGTCGGGGCCAGGACTGGTGGAGGCTTCGGAGACCCTGTCCCTCACCTGCACTGTGTCCGGCGACTCCACTGCTGCTTGTGACTATTTCTGGGGCTGGGTCCGGCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGGGGGTTTGTCACATTGTGCAGGTTACTACAATACTGGCTGGACCTACCACAACCCGTCTCTCAAGAGTCGGCTCACGATTTCACTCGACACCCCCAAGAATCAGGTCTTCCTGAAGTTAAATTCTGTGACCGCCGCGGACACGGCCATTTACTACTGTGCGCGATTCGACGGCGAAGTTTTGGTGTACCACGATTGGCCAAAGCCGGCCTGGGTCGACCTCTGGGGCCGGGGAACTTTGGTCACCGTCACCGTCTCCTCA;QSALTQPPSASGSPGQSISISCTGTSNRFVSWYQQHPGKAPKLVIYGVNK;CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCTCCATCTCCTGCACTGGAACCAGCAATAGGTTTGTCTCCTGGTACCAGCAACACCCAGGCAAGGCCCCCAAACTCGTCATTTATGGGGTCAATAAGCGCCCCTCAGGTGTCCCTGATCGTTTTTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCGTCTCTGGGCTCCAGACTGACGATGAGGCTGTCTATTACTGCAGCTCACTTGTAGGCAACTGGGATGTGATTTTCGGCGGAGGGACCAAGTTGACCGTCCTG;134.979421400036
PGT127;gp120 V3 // V3 glycan (V3g);3TWC(PGT127 complexed with Man(9));36 ;PGT128;Walker2011(21849977) ;Mutation greatly reduces PGT126 and PGT127 neutralization,PGT121-123, 125-128, 130, 131 sites important for neutralization,PGT127, PGT128 contacts,V3 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV4-39*07;;IGHJ5*02;19.0;FGGEVLVYRDWPKPAWVDL;IGLV2-8*01;IGLJ2*01,IGLJ3*01;10.0;SSLVGNWDV;L;PGT-127; ;QPQLQESGPGLVEASETLSLTCTVSGDSTGRCNYFWGWVRQPPGKGLEWI;CAGCCGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGGAGGCTTCGGAGACCCTGTCCCTCACGTGCACTGTGTCCGGCGACTCCACTGGTCGTTGTAATTATTTCTGGGGCTGGGTCCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTTTGTCCCACTGTAGAAGTTACTACAATACTGACTGGACCTACCACAACCCGTCTCTCAAGAGTCGACTCACTATTTCACTCGACACGCCCAAGAATCAGGTCTTCCTGAGATTGACCTCTGTGACCGCCGCGGACACGGCCACTTATTACTGTGCGCGATTCGGCGGCGAAGTTCTAGTGTACAGAGATTGGCCAAAGCCGGCCTGGGTCGACCTCTGGGGCCGGGGAACGCTGGTCACCGTCTCGAGC;QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQYPGKAPKLVIYEVNK;CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCACCATCTCCTGCACTGGAACCAGCAATAACTTTGTCTCCTGGTACCAACAATACCCAGGCAAGGCCCCCAAACTCGTCATTTATGAGGTCAATAAGCGCCCCTCAGGTGTCCCTGATCGTTTCTCTGGCTCCAAGTCTGGCAGCACGGCCTCCCTGACCGTCTCTGGACTCCAGGCTGACGATGAGGGTGTCTATTATTGTAGTTCACTTGTAGGCAACTGGGATGTGATTTTCGGCGGAGGGACCAAGTTGACCGTCCTA;95.8180588798695
PGT128;gp120 V3 // V3 glycan (V3g);5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195),3TYG(PGT128 complexed with glycosylated gp120),3TV3(PGT128 complexed with Man(9)),5ACO(PGT128 Fab in complex with BG505 SOSIP.664 Env trimer);36 ;PGT128;Walker2011(21849977) ;hypervariable loop characteristic correlations with bNAb sensitivity,Mutation affects neutralization of V3 mAbs,Mutation greatly reduces PGT128 neutralization,PGT121-123, 125-128, 130, 131 sites important for neutralization,PGT127, PGT128 contacts,PGT128 contacts,V3 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV4-39*07;;IGHJ5*02;19.0;FGGEVLRYTDWPKPAWVDL;IGLV2-8*01;IGLJ2*01,IGLJ3*01;10.0;GSLVGNWDVI;L;PGT-128; ;QPQLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVRQPPGKGLEWV;CAGCCGCAGCTGCAGGAGTCGGGCCCAACACTGGTGGAGGCTTCGGAGACTCTGTCCCTCACCTGCGCTGTGTCCGGCGACTCCACTGCTGCATGTAATTCTTTCTGGGGCTGGGTCCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGGTTGGGAGTTTGTCCCATTGTGCAAGCTATTGGAATCGTGGGTGGACCTACCACAACCCGTCTCTCAAGAGTCGGCTCACGCTTGCTCTCGACACACCCAAGAATCTGGTCTTCCTCAAATTAAATTCTGTGACTGCCGCGGACACGGCCACTTACTACTGTGCGCGATTCGGCGGCGAAGTTTTACGCTACACGGATTGGCCAAAGCCGGCCTGGGTCGACCTCTGGGGCCGGGGAACGCTGGTCACCGTCTCGAGC;QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNK;CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCACCATCTCCTGCACTGGAACCAGCAATAACTTTGTCTCCTGGTACCAGCAACACGCAGGCAAGGCCCCCAAGCTCGTCATTTATGACGTCAATAAGCGCCCCTCAGGTGTCCCTGATCGTTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCGTCTCTGGACTCCAGACTGACGATGAGGCTGTCTATTACTGCGGCTCACTTGTAGGCAACTGGGATGTGATTTTCGGCGGAGGGACCAAGTTGACCGTCCTA;173.521772925208
PGT130;gp120 V3 // V3 glycan (V3g);;36 ;PGT128;Walker2011(21849977) ;Mutation greatly reduces PGT130 neutralization,PGT121-123, 125-128, 130, 131 sites important for neutralization,V3 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV4-39*07;;IGHJ5*02;19.0;SGGDILYYYEWQKPHWFSP;IGLV2-8*01;IGLJ2*01,IGLJ3*01;10.0;SSLFGRWDVV;L;PGT-130; ;QVQLQESGPGLVKPAETLSLTCSVSGESINTGHYYWGWVRQVPGKGLEWI;CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTGCGGAGACCCTGTCCCTCACCTGCAGTGTCTCTGGAGAATCTATCAATACTGGTCATTACTACTGGGGCTGGGTCCGTCAGGTCCCAGGGAAGGGACTTGAGTGGATAGGTCATATCCATTATACGACGGCTGTCCTGCACAACCCGTCCCTCAAGAGTCGACTCACCATCAAAATTTACACGTTGAGAAACCAGATTACCCTGAGGCTCAGTAATGTGACGGCCGCGGACACGGCCGTCTATCACTGCGTACGATCCGGCGGCGACATCTTATATTATTATGAGTGGCAAAAGCCGCACTGGTTCTCTCCCTGGGGCCCGGGAATCCACGTCACCGTCTCGAGC;QSALTQPPSASGSLGQSVTISCNGTSSDIGGWNFVSWYQQFPGRAPRLII;CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCTTGGACAGTCAGTCACCATCTCCTGCAATGGAACCAGCAGTGACATTGGCGGTTGGAATTTTGTCTCCTGGTATCAACAGTTCCCGGGCAGAGCCCCCAGACTCATTATTTTTGAGGTCAATAAGCGGCCCTCAGGGGTCCCTGGTCGCTTCTCTGGCTCCAAGTCGGGCAATTCGGCCTCCCTGACCGTCTCTGGGCTCCAGTCTGACGATGAGGGTCAATATTTCTGCAGTTCACTTTTCGGCAGGTGGGATGTTGTTTTTGGCGGGGGGACCAAGCTGACCGTCCTA;142.8055029211
PGT135;gp120 V3 // V3 glycan (V3g);4JM4(Fab PGT135),4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab);39 ;PGT135;Walker2011(21849977) ;Mutation greatly reduces PGT135 neutralization,PGT135 contacts and sites,V3 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV4-39*07;;IGHJ5*02;18.0;HRHHDVFMLVPIAGWFDV;IGKV3-15*01;IGKJ1*01;9.0;QQYEEWPRT;K;PGT-135; ;QLQMQESGPGLVKPSETLSLSCTVSGDSIRGGEWGDKDYHWGWVRHSAGK;CAGTTGCAGATGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCTCTGAGTTGCACTGTCTCTGGTGACTCCATAAGGGGTGGCGAGTGGGGCGATAAAGATTATCATTGGGGCTGGGTCCGCCACTCAGCAGGAAAGGGCCTGGAGTGGATTGGGAGTATCCATTGGAGGGGGACCACCCACTACAAAGAGTCCCTCAGGAGAAGAGTGAGTATGTCGATCGACACGTCCAGGAATTGGTTCTCCCTGAGGCTGGCCTCTGTGACCGCCGCGGACACGGCCGTCTACTTTTGTGCGAGACACCGACATCATGATGTTTTCATGTTGGTCCCTATTGCGGGCTGGTTCGACGTCTGGGGCCCGGGAGTCCAGGTCACCGTCTCGAGC;EIVMTQSPDTLSVSPGETVTLSCRASQNINKNLAWYQYKPGQSPRLVIFE;GAAATTGTGATGACGCAGTCTCCCGACACCCTGTCTGTCTCTCCAGGGGAGACAGTCACACTCTCCTGCAGGGCCAGTCAGAATATTAACAAGAATTTAGCCTGGTACCAATACAAACCTGGCCAGTCTCCCAGGCTCGTAATTTTTGAAACATATAGCAAGATCGCTGCTTTCCCTGCCAGGTTCGTTGCCAGTGGTTCTGGGACAGAGTTCACTCTCACCATCAACAACATGCAGTCTGAAGATGTTGCAGTTTATTACTGTCAACAATATGAAGAGTGGCCTCGGACGTTCGGGCAAGGGACCAAGGTGGATATCAAA;51.0909722613057
PGT143;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;;84 ;PGT145;Walker2011(21849977) ;Mutation greatly reduces PGT143 neutralization,V2 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV1-8*01;;IGHJ6*02;32.0;GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV;IGKV2-28*01,IGKV2D-28*01;IGKJ1*01;9.0;MQGLNRPWT;K;PGT-143; ;QVQLEQSGAEVKKPGSSVKVSCKASGNTFSKYDVHWVRQATGQGLEWVGW;CAGGTGCAGCTGGAGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGAAACACCTTCAGTAAATATGATGTCCACTGGGTACGACAGGCCACTGGACAGGGGCTTGAATGGGTGGGATGGATGAGTCATGAGGGTGATAAGACAGAATCTGCACAGAGATTTAAGGGGCGAGTCACCTTCACGAGGGACACTTCCGCAAGCACAGCCTACATGGAACTGCGCGGCCTGACATCTGACGACACGGCCATTTATTATTGTACGAGAGGTTCAAAACATCGCTTGCGAGACTACGTTCTCTACGATGACTACGGCTTAATTAATTATCAAGAGTGGAATGACTACCTTGAATTTTTGGACGTCTGGGGCCATGGAACCGCGGTCACCGTCTCCTCA;DTVVTQSPLSLPVTPGEAASMSCTSTQSLRHSNGANYLAWYQHKPGQSPR;GATACTGTCGTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCATGTCCTGTACGTCGACTCAGAGCCTCCGTCATAGTAATGGAGCCAACTATTTGGCTTGGTACCAGCACAAACCAGGGCAGTCTCCACGACTCCTAATCCGTTTAGGTTCTCAACGGGCCTCCGGGGTCCCTGACAGATTCAGTGGCAGTGGATCAGGCACTCATTTTACACTGAAAATCAGTCGAGTGGAGCCTGAAGATGCTGCAATTTATTATTGCATGCAAGGTCTGAACCGTCCCTGGACGTTCGGCAAGGGGACCAAGTTGGAAATCAAA;165.653450382923
PGT145;gp120 V2 // V2 glycan(V2g) // V2 apex;3U1S(Fab PGT145);84 ;PGT145;Walker2011(21849977) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,hypervariable loop characteristic correlations with bNAb sensitivity,Mutation affects neutralization by V1V2 glycan mAbs,Mutation affects PG9-like Ab sensitivity,Mutation greatly reduces PGT145 neutralization,PG9-like antibodies require N160 for neutralization,PG9-like contacts,PGT145 escape mutations,Signature Analysis Summary,V2 Signature Analysis Summary;Walker2011(21849977) ;IMGT/V-QUEST SoDA2;IGHV1-8*01;;IGHJ6*02;31.0;GSKHRLRDYFLYNEYGPNYEEWGDYLATLDV;IGKV2-28*01,IGKV2D-28*01;IGKJ1*01;9.0;MQGLHSPWT;K;PGT-145; ;QVQLVQSGAEVKKPGSSVKVSCKASGNSFSNHDVHWVRQATGQGLEWMGW;CAGGTGCAGTTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGAAACAGTTTCAGTAATCATGATGTCCACTGGGTACGACAGGCCACTGGACAGGGGCTTGAATGGATGGGATGGATGAGTCATGAGGGTGATAAGACAGGCTTGGCACAAAAGTTTCAGGGCAGAGTCACCATCACGAGGGACAGTGGCGCAAGTACAGTCTACATGGAGTTGCGCGGCCTGACAGCTGACGACACGGCCATTTATTATTGTTTGACCGGCTCAAAACATCGCCTGCGAGATTATTTTCTGTACAATGAATATGGCCCCAATTATGAAGAGTGGGGTGACTACCTTGCGACTTTGGACGTCTGGGGCCATGGGACCGCGGTCACCGTCTCGAGC;EVVITQSPLFLPVTPGEAASLSCKCSHSLQHSTGANYLAWYLQRPGQTPR;GAGGTTGTCATAACTCAGTCTCCACTCTTCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCTTGTCTTGCAAGTGCAGCCACAGCCTCCAACATTCAACTGGAGCCAACTATTTGGCTTGGTACCTGCAGAGACCAGGGCAAACTCCACGCCTGTTGATCCATTTGGCCACTCATCGGGCCTCCGGGGTCCCTGACAGATTCAGTGGCAGTGGATCAGGCACAGATTTTACACTTAAAATCAGTCGAGTGGAGTCTGACGATGTTGGAACTTATTATTGCATGCAGGGTCTGCACAGTCCCTGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAA;217.286749746994
PGT151;fusion peptide // near gp41-gp120 interface;4NUG(Antibody PGT151);31 ;;Falkowska2014(24768347) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs,Mutation affects PG151 neutralization,PGT151-PGT158 sites of interaction,Sites affecting neutralization of PGT151;Falkowska2014(24768347) ;;IGHV3-30*04;;IGHJ6*02;28.0;ARMFQESGPPRLDRWSGRNYYYYSGMDV;IGKV2D-29*02;IGKJ4*01;9.0;MQSKDFPLT;K;PGT-151; ;RVQLVESGGGVVQPGKSVRLSCVVSDFPFSKYPMYWVRQAPGKGLEWVAA;CGGGTGCAGTTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCGTGAGACTTTCCTGTGTAGTCTCCGATTTCCCCTTCAGCAAGTATCCTATGTATTGGGTTCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCCATCTCCGGTGATGCCTGGCATGTGGTCTACTCAAATTCCGTGCAGGGCCGATTTCTCGTCTCCAGGGACAATGTCAAGAACACTCTATATTTAGAAATGAACAGCCTGAAAATTGAGGATACGGCCGTATATCGCTGCGCGAGAATGTTCCAGGAGTCTGGTCCACCACGTTTGGATCGTTGGAGCGGTCGAAATTATTACTATTATTCTGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCGAGC;DIVMTQTPLSLSVTPGQPASISCKSSESLRQSNGKTSLYWYRQKPGQSPQ;GACATTGTGATGACCCAGACTCCTCTCTCTTTGTCCGTCACCCCTGGACAGCCGGCCTCCATCTCCTGCAAGTCCAGTGAGAGCCTCCGACAAAGTAATGGAAAGACCTCTTTGTATTGGTATCGGCAGAAGCCAGGCCAGTCTCCACAACTCCTAGTGTTTGAAGTTTCTAATCGATTCTCTGGCGTGTCGGATAGGTTTGTTGGCAGCGGGTCAGGGACAGACTTCACACTGAGAATCAGCCGGGTAGAGGCTGAGGATGTTGGATTTTATTACTGCATGCAAAGTAAAGACTTCCCACTTACATTTGGCGGCGGGACCAAGGTGGATCTCAAA;249.221692302467
PGT152;fusion peptide // near gp41-gp120 interface;4NUJ(Antibody PGT152);31 ;;Falkowska2014(24768347) ;PGT151-PGT158 sites of interaction;Falkowska2014(24768347) ;;IGHV3-30*04;;IGHJ6*02;28.0;ARMFQESGPPRFDSWSGRNYYYYSGMDV;IGKV2D-29*02;IGKJ4*01;9.0;MQSKDFPLT;K;PGT-152; ;RVQLVESGGGVVQPGKSVRLSCVVSDFPFSKYPMYWVRQAPGKGLEWVAA;CGGGTGCAGTTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCGTGAGACTTTCCTGTGTAGTCTCTGATTTCCCCTTCAGCAAGTATCCTATGTATTGGGTTCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCCATCTCCGCTGATGCCTGGCATGTGGTCTACTCAGGCTCCGTGCAGGGCCGATTTCTCGTCTCCAGGGACAACTCCAAGAACATTCTGTATTTGGAAATGAACACCCTGAAAATTGAGGACACGGCCGTATATCGCTGCGCGAGAATGTTCCAGGAGTCTGGTCCACCACGTTTCGATTCTTGGAGCGGTCGAAATTACTACTATTACTCTGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCGAGC;DIVMTQTPLSLSVDPGQPASISCKSSQSLRQSNGKTSLYWYQQKPGQSPQ;GACATTGTGATGACCCAGACTCCTCTCTCTTTGTCCGTCGACCCTGGACAGCCGGCCTCCATCTCCTGCAAGTCCAGTCAGAGCCTCCGACAAAGTAATGGAAAGACCTCTTTGTATTGGTATCAGCAGAAGCCAGGCCAGTCTCCACAACTCCTAATATTTGAAGTTTCTAATCGATTCTCTGGCGTGTCGGATAGGTTTGTTGGCAGCGGGTCAGGGACAGACTTCACACTGAGAATCAGCCGGGTAGAGGCTGAGGATGTTGGATTTTATTACTGCATGCAAAGTAAAGACTTCCCACTCACCTTTGGCGGCGGGACCAAGGTGGATCTCAAC;250.25728477217
VRC-CH31;gp120 CD4BS;4LSP(VRC-CH31 complexed with gp120 (93TH057)),4LSQ(VRC-CH31 complexed with gp120 (93TH057/3514 chimera)),4LSR(VRC-CH31 complexed with gp120 (93TH057/KER2008 chimera));CH0219 ;VRC-CH31;Wu2011(21835983) ;Signature Analysis Summary,VRC-CH31 signature predictions (West2013);Wu2011(21835983) ;IMGT/V-QUEST JoinSolver;IGHV1-2*02;IGHD3-16*01;IGHJ4*02;15.0;;IGKV1-33*01;IGKJ2*01;5.0;;K;CH31, VRC-CH31 d0219; ;QVQLVQSGAAVRKPGASVTVSCKFAEDDDYSPYWVNPAPEHFIHFLRQAP;CAGGTGCAGCTGGTGCAGTCAGGGGCTGCCGTGAGGAAGCCTGGGGCCTCAGTGACTGTCTCCTGTAAATTCGCTGAAGACGACGACTACTCTCCATACTGGGTGAATCCGGCCCCTGAACATTTTATTCACTTTTTGCGACAGGCCCCTGGACAACAACTAGAGTGGCTGGCATGGATGAACCCAACGAATGGCGCCGTTAATTATGCATGGTACCTTAATGGCAGGGTCACGGCGACCAGGGACAGGTCCATGACTACAGCCTTTTTGGAAGTGAAGAGTCTAAGATCTGACGACACGGCCGTCTACTATTGTGCGAGGGCCCAGAAAAGGGGGCGGAGTGAGTGGGCCTACGCCCACTGGGGTCAGGGCACTCCGGTCGTCGTCTCGTCA;DIQMTQSPSSLSASLGDRVTITCQASRGIGKDLNWYQQKAGKAPKLLVSD;GACATCCAGATGACCCAGTCTCCATCGTCCCTGTCTGCATCACTCGGGGACAGAGTCACCATCACTTGCCAGGCGAGTCGGGGCATTGGCAAAGATTTAAATTGGTACCAGCAGAAAGCGGGAAAAGCCCCTAAGTTACTGGTCTCTGATGCATCCACTTTGGAAGGGGGGGTCCCATCAAGGTTCAGTGGGAGTGGATTTCACCAAAATTTTAGTCTGACTATCAGCAGCCTGCAGGCTGAGGATGTTGCAACATACTTCTGTCAACAATACGAGACTTTTGGCCAGGGGACCAAGGTGGACATCAAA;215.368296520393
VRC-PG04;gp120 CD4BS;3J5M(BG505 Env trimer with 3 PGV04 Fabs),4I3S(gp120 complexed with VRC-PG04 space group P21),4I3R(gp120 complexed with VRC-PG04 space group P3221),EMD-7107(PC64M4c054 SOSIP in complex with PGV04 Fab),EMD-8302(SOSIP trimer from patient AMC011 in complex with Fab from IgG PGV04),3SE9(VRC-PG04 complexed with gp120);74 ;VRC-PG04 ;Wu2011(21835983) ;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization,Mutation decreases binding to CD4BS mAbs,Signature Analysis Summary,VRC-PG04 alanine scanning,VRC-PG04 contacts,VRC-PG04 signature predictions (West2013);Mascola2012() ;IMGT/V-QUEST;IGHV1-2*02;IGHD2-8*02;IGHJ2*01;16.0;ARQKFYTGGQGWYFDLWGRGTLIVVSS;IGKV3-11*01;IGKJ5*01;5.0;QQLEF;K;PG-04, PG04, PGV04, VRC-PG-04, VRC-PG04 d74; ;QVQLVQSGSGVKKPGASVRVSCWTSEDIFERTELIHWVRQAPGQGLEWIG;CAGGTGCAGCTGGTGCAGTCTGGGTCTGGAGTGAAGAAGCCTGGGGCTTCGGTGAGAGTCTCCTGTTGGACCTCTGAGGACATCTTCGAAAGAACCGAGTTGATTCATTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATTGGGTGGGTGAAAACCGTCACTGGCGCCGTCAATTTTGGTTCACCAGATTTTCGACAGAGAGTCTCTCTGACCCGCGACAGGGACCTCTTCACAGCCCATATGGACATTCGCGGACTGACACAAGGCGACACGGCCACATATTTTTGCGCGAGACAGAAATTTTATACGGGCGGCCAAGGCTGGTACTTCGATCTCTGGGGCCGTGGAACCCTCATTGTTGTCTCGTCA;EIVLTQSPGTLSLSPGETASLSCTAASYGHMTWYQKKPGQPPKLLIFATS;GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCAGCCTCTCCTGCACGGCGGCCTCATATGGTCACATGACTTGGTATCAGAAAAAACCTGGCCAGCCTCCCAAACTCCTCATTTTTGCAACGTCCAAGAGGGCCAGTGGCATCCCAGACAGGTTCAGTGGCTCCCAGTTTGGTAAACAATATACTCTCACCATCACCAGAATGGAGCCTGAAGATTTTGCGAGATATTACTGTCAGCAACTTGAATTCTTCGGCCAGGGGACACGACTGGAGATTAGACGA;211.107920795746
VRC-PG20;gp120 CD4BS;4LSU(VRC-PG20 in complex with HIV-1 clade A/E 93TH057 gp120);IAVI 23 ;;Zhou2013a(23911655) ;;Zhou2013a(23911655) ;IgBlast IMGT/V-QUEST;IGHV1-02*02;;;12.0;RRSQDREWDFQH;IGLV2-14*01;IGLJ2*01;5.0;NAYEF;L;VRC-PG20 d23; ;QVHLMQSGTEMKKPGASVRVTCQTSGYTFSDYFIHWLRQVPGRGFEWMGW;CAAGTGCATTTAATGCAGTCTGGGACTGAAATGAAGAAGCCTGGGGCCTCAGTGAGGGTCACCTGTCAGACTTCTGGATACACCTTCAGCGACTACTTCATCCACTGGTTGCGACAAGTCCCCGGTCGAGGATTTGAGTGGATGGGTTGGATGAACCCTCAATGGGGTCAAGTCAACTATGCACGGACATTTCAGGGAAGAGTCACGATGACAAGAGACGTTTATAGGGAAGTTGCTTACTTGGACCTGAGGAGCCTGACATTTGCCGACACGGCCGTCTATTTCTGTGCGAGAAGAATGAGGTCCCAGGACCGCGAGTGGGACTTCCAGCACTGGGGCCAGGGCACCCGGATCATCGTTTCGTCA;QSALTQPPSVSGSPGQSITLSCTGASTSVAWYQQYADKAPRLIVFDGNKR;CAGTCTGCCCTGACTCAGCCTCCCTCCGTGTCTGGGTCTCCCGGACAGTCGATCACCCTCTCCTGCACTGGCGCCTCTACCTCTGTCGCCTGGTATCAACAATACGCAGACAAGGCCCCCCGACTCATCGTTTTTGATGGCAATAAGCGGCCCTCAGACATTTCTAGTCGCTTCTCTGGATCCCAGTCTGGCGGCACGGCCTCCCTGACCATTTCTGGACTCCAGAGTGAAGACGAGGCTTATTATCATTGTAATGCATTTGAATTCTTTGGCGGAGGGACCAAGTTGACCGTCCTCAGTCAG;202.615312149503
VRC01;gp120 CD4BS;5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01),4JPI(Fab VRC01 germline precursor),5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01),3NGB(VRC01 complexed with gp120),4LSS(VRC01 complexed with gp120 (KER2008)),4LST(VRC01 complexed with gp120 (ZM176)),4JPK(VRC01 germline precursor Fab complexed with gp120 outer domain);NIH45 ;VRC01 ;Wu2010(20616233) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,Electrostatic interactions with D368,hypervariable loop characteristic correlations with bNAb sensitivity,Mutation affects neutralization,Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization,Mutation decreases binding to CD4BS mAbs,Removal of N-linked glycosylation sites from the 426c Env confers binding to germline-reverted NIH45-46 and VRC01.,Sequence changes after immunotherapy with VRC01,Signature Analysis Summary,VRC01 alanine scanning,VRC01 contacts,VRC01 residue prediction,VRC01 signature predictions (West2013);Wu2010(20616233) ;IMGT/V-QUEST JoinSolver;IGHV1-02*02;IGHD3-16*01,IGHD3-16*02;IGHJ1*01,IGHJ2*01;14.0;;IGKV3-11*01;IGKJ2*01;5.0;;K;VRC01 d45, VRC-HIVMAB060-00-AB; Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.;QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGW;CAGGTGCAGCTGGTGCAGTCTGGGGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCGGTCATCGTCTCATCA;EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGS;GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAGCGA;216.328161989411
VRC03;gp120 CD4BS;5JXA(Ligand-free VRC03 antigen-binding fragment),3SE8(VRC03 complexed with gp120),5JOF(VRC03 gHVgLV antigen-binding fragment);NIH45 ;VRC01;Wu2010(20616233) ;Signature Analysis Summary,VRC03 contacts,VRC03 signature predictions (West2013);Li2012(22875963) ;IMGT/V-QUEST JoinSolver;IGHV1-2*02,IGHV1-2*04;IGHD3-22*01;IGHJ1*01;16.0;;IGKV3-20*01;IGKJ2*01;5.0;;K;VRC03 d45; Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.;QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGW;CAGGTGCAGCTGGTGCAGTCTGGGGCTGTGATTAAGACGCCTGGGTCCTCAGTGAAGATCTCATGTCGGGCTTCTGGATACAACTTTCGTGATTATTCGATCCATTGGGTCCGCCTCATTCCTGACAAGGGATTTGAGTGGATTGGATGGATTAAACCTCTGTGGGGTGCCGTCAGTTATGCCCGGCAACTTCAGGGCCGAGTCTCTATGACTCGACAATTATCTCAAGACCCAGACGACCCGGACTGGGGCGTTGCCTACATGGAGTTCAGTGGACTGACGCCCGCCGACACGGCCGAATATTTTTGTGTCCGGAGAGGGTCCTGTGATTATTGCGGAGACTTTCCCTGGCAATACTGGGGTCAGGGCACCGTCGTCGTCGTCTCGTCA;EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDT;GAAATTGTGTTGACGCAGTCTCCCGGCATCCTGTCTCTGTCTCCAGGAGAGACAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATGCTATGACGTGGTATCAGAAGAGACGTGGCCAGGTTCCCAGACTCCTGATCTACGATACATCTCGCAGGGCCTCTGGCGTTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGACTTCTTTCTCACGATCAACAAATTGGACCGGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGAGCGAGCTGGAAGTCCATCGA;113.443528616948
VRC06;gp120 CD4BS;4JB9(VRC06 in complex with HIV-1 gp120 core);NIH45 ;VRC01;Li2012(22875963) ;;Li2012(22875963) ;IMGT/V-QUEST JoinSolver;IGHV1-2*02,IGHV1-2*04;IGHD4-17*01;IGHJ1*01;17.0;;IGKV3-20*01;IGKJ2*01;5.0;;K;; ;EVQLVESGPVMRKPGSSMKISCATSGYNFRDFSIHWVRFNRRYGFEWIGW;GAGGTGCAGCTGGTGGAGTCTGGGCCTGTCATGAGGAAGCCTGGGTCCTCGATGAAGATCTCATGCGCGACTTCTGGATACAACTTTCGTGACTTTTCGATTCATTGGGTCCGTTTCAACCGTCGATATGGCTTTGAGTGGATCGGCTGGATCAAGCCTATGTGGGGTGCCGTCAATTATGCCCGCCAACTTCAGGGCCGCGTCTCAATGAGTCGTCTCTTTTCTCAGGACCTATATTATCCGGACAGGGGCACAGCCTACTTGGAATTCAGTGGACTGACGTCCGCCGACACGGCCGACTATTTCTGTGTGAGGCGGGGGTCTTCCTGTCCTCATTGCGGAGACTTCCATTTCGAACATTGGGGCCAGGGTACAGCCGTCGTCGTCTCGGCA;EIVLTQSPATLSLSPGERATLSCRASQGGNSLNWYQKRRGQTPRLLIYDT;GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGACATTCCTGAAAAATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTCACCATCACGAAAGTGGGCCCGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGACCACGCTGGAAATCAAT;58.1166808550639
VRC06b;gp120 CD4BS;4XNZ(VRC06B in complex with HIV-1 clade A/E strain 93TH057 gp120);NIH45 ;VRC01;Li2012(22875963) ;Signature Analysis Summary;Li2012(22875963) ;IMGT/V-QUEST JoinSolver;IGHV1-2*02,IGHV1-2*04;IGHD4-17*01;IGHJ1*01;17.0;;IGKV3-20*01;IGKJ2*01;5.0;;K;; ;QVQLVESGSAMRKPGSSVKISCRASGFNFREYSIHWVRLIPGRGLEWMGW;CAGGTGCAGCTGGTGGAGTCTGGGTCTGCGATGAGGAAGCCGGGGTCGTCAGTGAAGATCTCATGTCGGGCTTCTGGATTCAATTTTCGCGAATATTCGATACATTGGGTCCGACTGATTCCTGGCAGGGGACTTGAGTGGATGGGGTGGATAAAGGGTATGTGGGGAGCCGTCAATTATGCCCGGCAACTTCAGGGCCGGGTCTCTATGACTCGACAATTGTCTCAGGACCCAGACGACCCAGACTGGGGCGTCGCCTACCTGGACTTCAGTGGACTGACGTCCGGCGATACAGGCGAATATTTTTGTGTGAGAAAAGGACCCTCCTGTCCTCACTGCGGAGACTTCCACTGGCAACATTGGGGTCAGGGCACACTCGTCGTCGTCTCGACA;EIVLTQSPGTLSVSPGERATLFCKASQGGNSLSWYQKRRGQPPRLLIYDT;GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTGTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATTCTTTAAGTTGGTATCAGAAGAGACGTGGCCAGCCTCCCAGACTCCTCATCTACGATACATCTCGCAGGGCCTCTGGCATTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGATTTCTCTCTCACGATCACCAAAGTGGACCGGGACGATTTCGCACTCTACTTCTGTCAACAATTTGAATTTTTTGGCCTGGGGACCGCGCTGGAAATCAAT;104.29400201791
VRC07;gp120 CD4BS;4OLV(VRC07-G54F in complex with 93TH057 gp120),4OLW(VRC07-G54H in complex with 93TH057 gp120),4OLX(VRC07-G54L in complex with 93TH057 gp120),4OLY(VRC07-G54R in complex with 93TH057 gp120),4OLZ(VRC07-G54W in complex with 93TH057 gp120),4OM0(VRC07-G54Y in complex with 93TH057 gp120),4OM1(VRC07-I30Q, G54W, S58N in complex with 93TH057 gp120),4OLU(VRC07 in complex with 93TH057 gp120);NIH45 ;VRC01;Rudicell2014(25142607) ;hypervariable loop characteristic correlations with bNAb sensitivity,Signature Analysis Summary;Rudicell2014(25142607) ;IMGT/V-QUEST;IGHV1-02*02;;;16.0;CTRGKYCTARDYYNWDFEH;IGKV3-20*01;;;;K;; ;QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGW;CAGGTGCGACTGTCGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGACTCGATGAGAATTTCTTGTCGGGCTTCGGGATACGAATTTATTAATTGTCCAATAAATTGGATTCGGCTGGCCCCCGGAAAAAGGCCTGAGTGGATGGGATGGATGAAGCCTAGGGGGGGGGCCGTCAGTTACGCACGTCAACTTCAGGGCAGAGTGACCATGACTCGAGACATGTATTCCGAGACAGCCTTTTTGGAGCTCCGTTCCTTGACATCCGACGACACGGCCGTCTATTTTTGTACTCGGGGAAAATATTGCACTGCGCGCGACTATTATAATTGGGACTTCGAACACTGGGGCCAGGGCACCCCGGTCACCGTCTCGTCA;EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGS;;257.35094379428
VRC13;gp120 CD4BS;4YDJ(44-VRC13.01 in complex with HIV-1 clade AE strain 93TH057 gp120);44 ;;Zhou2015(26004070) ;Signature Analysis Summary,VRC13 contacts;Zhou2015(26004070) ;IMGT/V-QUEST;IGHV1-69;;;;;IGLV2-14;;;;L;44-VRC13.01; ;QVQLVQPGTAMKSLGSSLTITCRVSGDDLGSFHFGTYFMIWVRQAPGQGL;CAGGTGCAGCTGGTGCAGCCCGGGACTGCGATGAAGTCTCTTGGATCATCACTGACGATCACTTGCAGAGTCTCCGGAGACGACCTCGGCTCTTTCCACTTCGGCACTTATTTTATGATCTGGGTGCGTCAAGCCCCTGGACAGGGCCTTGAGTACATGGGAGGCATCCTCCCCTCCACGAAGACACCCACTTACGCGCACAAATTTCGAGGCCGCGTCTCTATTTCCGCTCCCGGGGTTCCGCCCGTGCTGTCCCTCGCGCTGACCAACCTCACATACGACGACACGGCCACCTACTTCTGTGCGCGCGAGAGGGGGCGACATTTTGAGCCAAAGAACAGGGATAATCTGGAAGGCAAATTTTTCGATTTATGGGGTCGTGGCACCTTCGTTCGCGTCTCGCCG;;;240.690604396845
VRC16;gp120 CD4BS;4YDK(C38-VRC16.01 in complex with HIV-1 clade AE strain 93TH057 gp120);C38 ;;Zhou2015(26004070) ;Signature Analysis Summary,VRC16 contacts;Zhou2015(26004070) ;IMGT/V-QUEST;IGHV3-32;;;;;IGKV1-39;;;;K;C38-VRC16.01; ;EVQLSESGGGFVKPGGSLRLSCEASGFTFNNYAMGWVRQAPGKGLEWVSV;GAGGTGCAGTTATCAGAGTCGGGGGGAGGCTTCGTAAAGCCGGGGGGGTCCCTGAGACTCTCCTGTGAGGCCTCTGGATTCACCTTCAATAATTATGCCATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCTGTGACGAGTGCTCATGGTGGTAGTGCATACTTTGGAGAATTCGTGAAGGGCCGCTTCACCATGTCCAGAGACCACTTCATAGACACGGTCTACTTGGAAATGAACAGACTGACAGTCGAGGACACGGCCGTCTACTACTGCGTCAGAGTGACATTTTACCATGAGGGCAGTGGCTACTATTATCGTGCCGGGAATTACTTTGATTCCTGGGGCCAGGGAACCCTAGTCATCGTCTCCGCA;;;94.9121359965181
VRC18;gp120 CD4BS;4YDL(C38-VRC18.02 in complex with HIV-1 clade AE strain 93TH057 gp120);C38 ;;Zhou2015(26004070) ;VRC18 contacts;Zhou2015(26004070) ;IMGT/V-QUEST;IGHV1-2;;;;;IGKV3-20;;;;K;C38-VRC18.02; ;QVRLVQSGNQVRKPGASVRISCEASGYKFIDHFIHWVRQVPGHGLEWLGW;CAGGTGCGATTGGTCCAATCTGGAAATCAAGTGAGGAAGCCTGGGGCCTCAGTGAGAATCTCCTGCGAGGCTTCCGGGTACAAATTCATCGACCACTTTATCCATTGGGTGCGTCAAGTCCCCGGTCACGGTCTTGAGTGGCTGGGCTGGATCAATCCCCGTGGCGGTGGCGTAAATTATTCACGAAGTTTTCAGGGGAAACTCTCCATGACCATGACAAGGGACAACTTCGAAGAGACAGCCTACCTGGACCTCAGTAAATTGAATCCTGGCGACACGGCCGTGTATTTCTGCGCGAGAGGATTTGCCGGTTATGAGTGGAGTTTCATCTGGGGTCAGGGAACTCTGGTCATTGTCTCCTCT;;;134.309854506056
VRC26.01;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;4OCR(Fab CAP256-VRC26.01);CAP256 ;VRC26;Doria-Rose2014(24590074) ;CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;35.0;CAKDVGDYKSDEWGTEYYDISISYPIQDPRAMVGAFDLW;IGLV51*02;;;;L;CAP256-VRC26.01; ;EVQVVESGGGVVQPGRSLRLSCTASGFTFSNFAMGWVRQAPGKGLEWVAF;GAAGTGCAGGTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTACAGCCTCTGGATTCACTTTCAGCAACTTTGCCATGGGCTGGGTCCGCCAGGCTCCGGGCAAGGGTCTGGAGTGGGTGGCCTTTATATCATCTGATGGAAGTAATAAAAACTATGGAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGGTGTTCCTGCAAATGAACAGTCTGAGAGTTGAGGACACGGCTTTGTATTACTGTGCGAAAGATGTGGGAGACTACAAAAGTGATGAGTGGGGGACGGAATATTATGATATTTCGATTTCTTACCCTATTCAAGACCCACGGGCCATGGTTGGAGCTTTTGATCTCTGGGGCCAAGGGACAATGGTCACCGTCTCTCC;QSVLTQPPSVSAAPGQKVTISCSGSSSTIGNNYVSWYRLLPGTAPKLLIY;CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCACCATTGGGAATAATTATGTCTCCTGGTACCGGCTACTCCCAGGAACAGCCCCCAAACTCCTCATCTATAAAAATGATAACCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCAGCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGGATACCAGCCTGAGTGGTGGCGGTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG;41.4896657190265
VRC26.03;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;4OD1(Fab CAP256-VRC26.03);CAP256 ;VRC26;Doria-Rose2014(24590074) ;CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;35.0;CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDGW;IGLV51*02;;;;L;CAP256-VRC26.03; ;EVQLVESGGGVVQPGKSLRLSCAASRFSFNRYGMHWVRQAPGKGLEWVAA;GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCCTGAGACTCTCCTGTGCAGCCTCTCGATTCAGTTTTAATAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCCATATCATATGATGGAACTGATAAATATCATGCAGATAAAGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTCTCTATTACTGTGCGAAAGATTTGCGAGAGGACGAATGTGAAGAGTGGTGGTCGGATTATTACGATTTTGGGAAACAGCTCCCTTGCCGAAAGTCACGGGGCGTGGCTGGAATTTTTGATGGCTGGGGCCAAGGGACAATGGTCACCGTCTCTTC;QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNFVSWYQQRPGTAPKILIY;CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGCAATAATTTTGTATCCTGGTACCAGCAGCGCCCAGGAACAGCCCCCAAGATCCTCATTTATGAAAATAACAAGCGACCCTCAGAGACTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGCCTCCAGACTGCGGACGAGGCCGAATATTACTGCGCCACATGGTCTGCCAGCCTGAGCTCCGCGCGTGTCTTCGGAACTGGGACCAGGATCACCGTCCTAG;138.926289388435
VRC26.06;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;4OCW(Fab CAP256-VRC26.06);CAP256 ;VRC26;Doria-Rose2014(24590074) ;CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;36.0;CARDLRELECEEWTLYNYYDFGSRGPCVDPRGVAGSFDVW;IGLV51*02;;;;L;CAP256-VRC26.06; ;EVQLIESGGGVVQPGRSLRLSCGASGFSFNNYGMHWVRQAPGKGLEWVAG;GAGGTGCAGCTGATTGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGGAGCGTCTGGATTCAGCTTCAATAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGGTATTTCCTTTGCTGGAATCAAGAAATACTATGGAACTTCCGTGAAGGGCCGATTCACCATCTCCCGAGACAATTCCAAGAACAATTTCTATCTGCAAATGAACAGCCTGCGAGTTGAGGACACGGCTCTCTATTATTGTGCGAGAGATCTGCGAGAATTGGAATGTGAAGAGTGGACACTATATAATTATTATGACTTTGGAAGTCGAGGCCCTTGTGTAGACCCACGGGGCGTGGCTGGATCTTTTGATGTCTGGGGCCAGGGGACAATGGTGACCGTCTCCTC;QSVLTQPPSVSAAPGQKVTISCSGSTSKIGQNSVSWYQQLPGTAPKLLIY;CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCACTTCCAAAATTGGGCAAAACTCTGTATCTTGGTACCAGCAACTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATGACCGGCGACCCTCGGGGACTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGAATATTACTGCGAAACATGGGATGGCAGCGGGGGTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG;40.8972289196856
VRC26.08;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;;CAP256 ;VRC26;Doria-Rose2014(24590074) ;CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites,hypervariable loop characteristic correlations with bNAb sensitivity,V2 Signature Analysis Summary;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;37.0;CVRDQREDECEEWWSDYYDFGRELPCRKFRGLGLAGIFDIW;IGLV51*02;;;;L;CAP256-VRC26.08; ;EVQLVESGGGVVQPGRSLTLSCAASQFTFSNYGMHWVRQAPGKGLEWVAS;GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCACTTTTTCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAAGTGTATCAAATGATGGAACCAAGAAATATCATGGAGATTCCGTGTGGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACACTGTTTCTACAAATGAGCAGCCTGCGAGCTGAGGACACGGCTGTATATTTCTGTGTGAGAGATCAACGAGAAGACGAGTGTGAAGAGTGGTGGTCGGATTATTATGATTTTGGGAGAGAGCTCCCTTGCCGAAAATTCCGGGGCCTGGGCCTGGCTGGAATTTTTGATATCTGGGGCCACGGGACAATGGTCACCGTCTCTTC;QSALTQPPSVSAAPGQKVTISCSGNSSNIGNNFVSWYQQVPGTAPKLLLY;CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCCGGAAACAGCTCCAACATTGGGAATAATTTTGTATCCTGGTACCAGCAAGTCCCAGGAACAGCCCCCAAACTCCTCCTGTATGAAACTTACAGGCGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTACTACTGCACAGTATGGGGTGTCAGGAAGGGTGTCGGCGCTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG;207.616719235857
VRC26.09;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;;CAP256 ;VRC26;Doria-Rose2014(24590074) ;BG505 mutants obtained introducing disulfide bonds either within the V2 loop or between the V1 and V2 loops,CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites,VRC26.09 escape mutations;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;37.0;CVKDQREDECEEWWSDYYDFGRELPCRKSRGLGLAGIFDMW;IGLV51*02;;;;L;CAP256-09, CAP256.09, CAP256-VRC26.09; ;EVQLVESGGGVVQPGRSLTLSCAASQFNFANYGMHWVRQAPGKGLEWVAS;GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCAATTTTGCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGATTGGAGTGGGTGGCAAGTATATCAAATGATGGAACGAAGAAATATCATGAAGAATCCGTGTGGGGCCGATTCACCATCTCCAAAGACAATTCCAAGAGCACACTATTTCTACAAATGAACAGCCTGCGAATTGAGGACACGGCCCTATATTTCTGTGTGAAAGATCAACGAGAGGACGAATGTGAAGAGTGGTGGTCGGATTATTATGATTTTGGGAGAGAGCTCCCTTGCCGAAAGTCCCGGGGCCTGGGCCTGGCTGGAATCTTTGATATGTGGGGCCACGGGACAATGGTCACCGTCTCTTC;QSALTQPPSVSAAPGQKVTISCSGNSSNIGNNFVSWYQQLPGTAPKLLIY;CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAATAGTTCCAACATTGGGAATAATTTTGTATCCTGGTACCAGCAACTCCCGGGGACAGCCCCCAAACTCCTCATATATGAAAATAACAGGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCAGCGGACTCCAGACTGGGGACGAGGCCGACTATTGGTGCGCTGTTTGGGGTGTCAGGCGGGGTGCCGGCGCTGTCTTCGGAGCTGGGACCAAGGTCACCGTCCTAG;198.72577026705
VRC26.25;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;5DT1(Fab CAP256-VRC26.25);CAP256 ;VRC26;Doria-Rose2016(26468542) ;CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites,hypervariable loop characteristic correlations with bNAb sensitivity,V2 Signature Analysis Summary,VRC26.25 neutralization associated sites;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;36.0;CAKDLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIADNW;IGLV51*02;;;;L;CAP256-VRC26.25; ;QVQLVESGGGVVQPGTSLRLSCAASQFRFDGYGMHWVRQAPGKGLEWVAS;CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTGCAGCCTCTCAATTCAGGTTTGATGGTTATGGCATGCACTGGGTCCGCCAGGCCCCAGGCAAGGGGCTGGAGTGGGTGGCATCTATATCACATGATGGAATTAAAAAGTATCACGCAGAAAAAGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTACAAATGAACAGCCTGCGACCTGAGGACACGGCTCTCTACTACTGTGCGAAAGATTTGCGAGAAGACGAATGTGAAGAGTGGTGGTCGGATTATTACGATTTTGGGAAACAACTCCCTTGCGCAAAGTCACGCGGCGGCTTGGTTGGAATTGCTGATAACTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA;QSVLTQPPSVSAAPGQKVTISCSGNTSNIGNNFVSWYQQRPGRAPQLLIY;CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAACACCTCCAACATTGGCAATAATTTTGTGTCCTGGTACCAACAGCGCCCCGGCAGAGCCCCCCAACTCCTCATTTATGAAACTGACAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGCTTCCAAGTCTGGTACGTCAGGCACCCTGGCCATCACCGGGCTGCAGACTGGGGACGAGGCCGATTATTACTGCGCCACATGGGCTGCCAGCCTGAGTTCCGCGCGTGTCTTCGGAACTGGGACCAAGGTCATCGTCCTA;282.330344573013
VRC26.26;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;;CAP256 ;VRC26;Doria-Rose2016(26468542) ;CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites,hypervariable loop characteristic correlations with bNAb sensitivity,V2 Signature Analysis Summary;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;37.0;CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDVW;IGLV51*02;;;;L;CAP256-VRC26.26; ;EVQLVESGGGIVQPGRSLTLSCVASQFAFSHYGMHWVRQAPGKGLEWVAS;GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCATAGTCCAGCCTGGGAGGTCCCTGACACTGTCTTGTGTAGCCTCTCAATTCGCTTTTTCGCATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCCAGTATCTCAAGGGATGAGACCAAGAAATATCATGGAGATTCCGTGTGGGACCGATTCAGTATCTCCAGAGACAATTCCAAGAATACCCTGTTTCTACAAATGAACAGCCTGCGAGCTGAGGACACGGCACTATATTTCTGTGTGAGAGATCAGCGAGAAGACGAATGTGAGGAGTGGTGGTCGGACTATTATGATTTTGGGAAAGAACTCCCTTGCCGAAAATTCCGGGGCCTGGGCCTGGCTGGAATTTTTGATGTCTGGGGCCACGGGACAATGGTCATCGTCTCTTCA;QSALTQPPSVSAAPGQKVSISCSGNNSNIGNNFISWFQQFPGTAPKPLIY;CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCTCCATCTCCTGCTCTGGAAACAACTCAAACATTGGGAATAACTTTATATCCTGGTTCCAGCAATTCCCAGGAACAGCCCCCAAACCCCTCATATATGAAACTTACAAGCGACACTCAGGTATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTATTACTGCGCAACATGGGGTGTCAGGCAGGGTGTCGGCGCTCTCTTCGGAACTGGGACTAAGGTCACCGTCCTA;196.075939141355
VRC26.27;gp120 V2 // V2 glycan(V2g) // V2 apex,quaternary structure;;CAP256 ;VRC26;Doria-Rose2016(26468542) ;CAP256-VRC26 lineage epitope,CAP256-VRC26 lineage escape mutations,CAP256-VRC26 lineage neutralization-associated sites;Doria-Rose2016(26468542) ;IMGT/V-QUEST;IGHV3-30*18;;;37.0;CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDIW;IGLV51*02;;;;L;CAP256-VRC26.27; ;QKQLVESGGGVVQPGRSLTLSCAASQFPFSHYGMHWVRQAPGKGLEWVAS;CAGAAGCAGTTGGTGGAGTCTGGGGGAGGCGTAGTCCAGCCTGGGAGGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCCCTTTTTCGCATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAAGTATTACAAATGATGGGACCAAGAAATATCATGGAGAGTCCGTGTGGGACCGATTCAGGATCTCCAGAGACAATTCCAAGAATACACTCTTTCTACAAATGAACAGCCTGCGAGCTGAGGACACGGCACTATATTTCTGTGTGAGAGATCAGCGAGAAGACGAATGTGAAGAGTGGTGGTCGGATTATTATGATTTTGGGAAAGAACTCCCTTGCCGAAAATTCCGGGGCCTGGGCCTGGCTGGAATTTTTGATATCTGGGGCCACGGGACAATGGTCATCGTCTCATCA;QSVLTQPPSVSAAPGQKVSISCSGNNSNIGNNFISWFQQFPGTAPKPLIY;CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCTCCATCTCCTGCTCTGGAAACAATTCAAACATTGGGAATAACTTTATATCCTGGTTCCAGCAATTCCCAGGAACAGCCCCCAAACCCCTCATATATGAAACTTACAGGCGACACTCAGGTATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTATTACTGCGCAACATGGGGTGTCAGGCAGGGTGTCGGCGCTCTCTTCGGAACTGGGACTAAGGTCACCGTCCTA;223.913178751737
VRC34.01;fusion peptide // near gp41-gp120 interface;5I8C(BG505 Fusion Peptide in Complex with VRC34.01 Fab),5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab),5I8E(VRC34.01 Fab);N123 ;VRC34;Kong2016a(27174988) ;Mutation reduces binding, reduces neutralization, or confers escape from fusion peptide directed Mabs,Sites affecting neutralization of VRC34,VRC34.01 mutations affect neutralization;Kong2016a(27174988) ;IMGT/V-QUEST;IGHV1-2*02;;IGHJ6*02;;ARDKYYGNEAVGMDVW;IGKV1-9*01;IGKJ4*01;;QHMSSYPLTF;K;N123-VRC34.01; ;QEVLVQSGAEVKKPGASVKVSCRAFGYTFTGNALHWVRQAPGQGLEWLGW;CAGGAGGTACTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAGGGCTTTTGGATATACCTTTACCGGCAATGCTCTGCACTGGGTTCGGCAGGCCCCTGGGCAAGGTCTTGAGTGGCTGGGGTGGATCAACCCTCACAGTGGTGACACAACCACTTCACAGAAATTTCAGGGCAGGGTCTACATGACCAGGGACAAGTCCATCAACACAGCCTTTTTGGACGTGACCAGGCTAACATCTGACGACACGGGCATATATTATTGTGCGAGAGACAAGTACTATGGTAATGAGGCAGTCGGAATGGACGTCTGGGGCCAGGGGACCTCGGTCACCGTCTCCTCAG;DIQLTQSPSFLSASVGDKVTITCRASQGVRNELAWYQQKPGKAPNLLIYY;GACATCCAGTTGACCCAGTCTCCATCCTTCCTTTCTGCCTCTGTAGGAGACAAGGTTACGATCACTTGCCGGGCCAGTCAGGGCGTTCGCAATGAGTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAATCTCCTCATCTATTATGCATCCACTTTGCAAAGTGGGGTCCCGTCAAGATTCAGCGCCACTGGATCTGGGACACACTTCACTCTCACAGTCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACACATGAGCAGTTACCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC;124.800994680303
VRC38.01;gp120 V1-V2;5EWI(Fab VRC38.01),5VGJ(Fab VRC38.01 bound to a scaffolded WITO V1V2 domain);N90 ;VRC38;Cale2017(28514685) ;Mutation affects neutralization by V1V2 glycan mAbs,VRC38.01 contacts;Cale2017(28514685) ;Cloanalyst IMGT/V-QUEST;IGHV3-13*01;;IGHJ6;16.0;GPESGWFYHYYWGLGV;IGKV2-28*01;IGKJ4;10.0;MEARQTPRLT;K;N90-VRC38.01; ;EVQLVESGGKLVQPGGSLRLSCEASGESVGDNDMHWVRQVAGKGLEWVSS;GAAGTGCAGCTGGTGGAGTCTGGGGGAAAGTTGGTTCAGCCGGGGGGGTCCCTGAGACTCTCGTGTGAAGCCTCTGGAGAAAGTGTCGGTGACAACGACATGCACTGGGTCCGCCAAGTCGCAGGAAAAGGTTTGGAGTGGGTCTCATCTATCGGAAGTTCTGGTGACACATATTATATAGACGCCGTTAAGGGCCGATTCACCGTCTCCAGAGACAAAGGCAGGAATTCGGTGTATCTCCAAATGAAGACCCTGACAGTCGGAGACACGGGTGTTTATTTCTGTGTCAGAGGGCCTGAAAGTGGTTGGTTCTATCACTACTACTGGGGTCTGGGCGTCTGGGGCCGAGGGACCACGGTCACCGTCTCCTCA;DLLMTQSPHSLAVTPGEPASISCRSSQSLLLGNGRNYLDWYVQKPGQSPQ;GATCTTCTGATGACTCAGTCTCCACACTCCCTGGCCGTCACCCCTGGAGAGCCGGCCTCCATTTCCTGCAGGTCTAGTCAGAGCCTCCTCCTTGGTAACGGAAGGAACTATTTGGATTGGTATGTGCAGAAGCCAGGCCAGTCTCCACAACTCTTGATCTACCTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACATATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGCTTTTATTATTGCATGGAAGCTCGACAAACTCCACGGCTCACTTTCGGCGGAGGGACCAAACTAGAGATCAGA;96.7645456835195
b12;gp120 CD4BS;1N0X(B12 complexed with mimotope),1HZH(B12 unliganded),3RU8(Fab b12 with epitope scaffold),2NY7(gp120 complexed with Fab b12);b ;b12;Burton1991(1719545) ;b12 contacts,b12 signature sites,IGg1b12 signature predictions (West2013),Mutation affects neutralization,Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization,Mutation decreases binding to CD4BS mAbs,Signature Analysis Summary;Wu2010(20616233) ;IMGT/V-QUEST JoinSolver;IGHV1-03*01;IGHD3-10*02;IGHJ6*03;20.0;;IGKV3-20*01;IGKJ2*01;9.0;;K;1b12, b12, b4/12, Fab b12, Ib12, IgG1 b12, IgG1-b12, IgGB12, MAb IgG1b12; ;LVQSGAEVKKPGASVKVSCQASGYRFSNFVIHWVRQAPGQRFEWMGWINP;CTCGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCTTGTCAGGCTTCTGGATACAGATTCAGTAACTTTGTTATTCATTGGGTGCGCCAGGCCCCCGGACAGAGGTTTGAGTGGATGGGATGGATCAATCCTTACAACGGAAACAAAGAATTTTCAGCGAAGTTCCAGGACAGAGTCACCTTTACCGCGGACACATCCGCGAACACAGCCTACATGGAGTTGAGGAGCCTCAGATCTGCAGACACGGCTGTTTATTATTGTGCGAGAGTGGGGCCATATAGTTGGGATGATTCTCCCCAGGACAATTATTATATGGACGTCTGGGGCAAAGGGACCACGGTCATCGTCTCCTCAGCCTCCACCAAG;EIVLTQSPGTLSLSPGERATFSCRSSHSIRSRRVAWYQHKPGQAPRLVIH;GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTCTGTCTCCAGGGGAAAGAGCCACCTTCTCCTGTAGGTCCAGTCACAGCATTCGCAGCCGCCGCGTAGCCTGGTACCAGCACAAACCTGGCCAGGCTCCAAGGCTGGTCATACATGGTGTTTCCAATAGGGCCTCTGGCATCTCAGACAGGTTCAGCGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCACCAGAGTGGAGCCTGAAGACTTTGCACTGTACTACTGTCAGGTCTATGGTGCCTCCTCGTACACTTTTGGCCAGGGGACCAAACTGGAGAGGAAA;70.9283798350944
b13;gp120 CD4BS;3IDY(gp120 core in complex with b13),3IDX(gp120 core in complex with b13);b ;;Burton1991(1719545) ;Impact of Y177A/Y173A and Y177F/Y173F on non-neutralizing and neutralizing Abs;;;;;;;;;;;;;; ;LEQSGEAVVQPGTSLRLSCAASGFTFRNYAMHWVRQAPGKGLEWVALIKY;CTCGAGCAGTCTGGGGAAGCCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGGAACTATGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTTGCACTTATAAAATATGATGGAAGAAATAAGTACTACGCAGATTCCGTGAAGGGCCGATTCAGCATTTCCAGAGACAATTCCAAGAACACGTTGTATCTGGAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTCTATTACTGTGCGAGAGATATTGGGTTAAAGGGCGAGCATTACGACATTTTGACTGCTTACGGCCCCGACTACTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCAGCCTCCACCAA;DIQMTQSPSSLSASVGDRVTITCQASQDIRNYLNWYQQKPGKAPKLLIYD;;1.34840931770839
3BNC55;gp120 CD4BS;;3 ;3BNC117;Scheid2011(21764753) ;3BNC55 signature predictions (West2013),Signature Analysis Summary;Scheid2011(21764753) ;;IGHV1-2;IGHD3-3,IGHD6-19,IGHD5-12;IGHJ2,IGHJ6;10.0;RHSDYCDFDI;IGKV1D-33;IGKJ1,IGKJ3;5.0;QVYEF;K;; ;QVQLVQSGTAVKRPGASVRVSCQASGYTFTDYFIYWWRQAPGQGLEWLGW;CAGGTGCAACTGGTGCAGTCTGGGACTGCGGTGAAGAGACCTGGGGCCTCAGTGAGGGTCTCCTGCCAGGCTTCTGGATACACATTTACCGACTACTTTATTTATTGGTGGCGACAGGCCCCTGGACAAGGCCTGGAATGGCTGGGCTGGATCAACCCTCTGACTAGTCAGCCAAGTTATCCTTCCAGATTTCAGGGCAGACTCACCCTGACCCGGGACACATTCGACGAGATGCTTTACATGGACCTGAGAGGACTCAGATCTGACGACACGGGCATTTATTTCTGTGCGAGACGCCATAGCGACTATTGCGATTTCGACATCTGGGGCAGTGGCACCCAAATTATTGTCTCTTCAGCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAG;;GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAAAGTCACCATCACTTGTCAGACAAGTGCAGGGTATTTAAATTGGTATCAACAAAGACGAGGGAGAGCCCCAAAACTCCTGATGTACGATGGATCCAGATTGGTAACAGGGGTCCCATCAAGGTTCAGTGGAAGACGGTGGGGGACACAATATAATTTGACCATCGGAAGCCTGCAGCCTGAAGATATTGCAACATATTATTGTCAAGTGTATGAGTTTTTCGGCCCTGGGACCAGACTGGATTTAAAAAGTACGGTGGCTGCACTATCTGTCTTCCTCTGG;150.025100361271
NC37;quaternary structure;;EB354 ;;Freund2017(28100831) ;;Freund2017(28100831) ;IMGT/V-QUEST;IGHV1-2,IGHV1-46;;;19.0;DNFGTRPVPGRGYYYGMDV;IGKV3-20;;;;K;354NC37; ;;CAGGTGCGCCTGGTGCAGTCGGGGGGTCAGGTGAGGAAGCCTGGGGCCTCAGTGACAATCTCCTGCGAGGCCGATGGATATGAATTCCCCGATTATTATATTCACTGGGTGCGACTGGCCCGTGGACGAGGGCCTGAGTGGCTGGGCCTCATCAAAGTAGGTCACGGTGGCGGCGCTATGTACGCACCGAGTTTACAGGGGAGAATCTCCATGTCTAGAGACATACACACGACCACCGCATACATGACTCTGCAGAGACTGACACACGACGACACGGCCACTTATTATTGTTCGCGAGATAACTTCGGGACTCGCCCAGTGCCTGGTCGGGGATATTATTACGGTATGGACGTCTGGGGCCAAGGGACTGCGATCATCGTCTCCTCG;;AAATTGTGTTGACGCAGTCTCCAGGCATCCTGTCTTTGGCTCCTGGGGAGCGAGCGTCCCTCTCTTGCAGGGCCAGTTACGGTCTTGACACCAGTCATTTAGCCTGGTTTCAGCACAAACCTGGCCGGCCTCCCAGGCTGCTCATCTATGGGACATCAAGTCGGCCCCCTGGCGTCCCAGACAGGTTTCGTGGCAGTGGGTCTGGGACGGACTTCACTCTCACCATTACCAAGTTGGAGCCTGAAGATTTTGCGGTTTATTACTGTCAGAACTCTGGCGGTGGAACACCGTTAATTTTCGGCCCTGGGACCAAAGTGGATATCAAAC;86.9039266461645
